Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934

For the quarterly period ended June 30, 2024

Commission File No. 000-22179

GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		58-2029543
(State or other jurisdiction of incorporation or organization)		I.R.S. Employer Identification No.)

5835 Peachtree Corners East, Suite B

Peachtree Corners, Georgia 30092

(Address of principal executive offices) (Zip Code)

(770) 242-8723

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No☐

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

As of August 10, 2024, the registrant had 56,550,370 shares of Common Stock, $0.001 par value per share, outstanding.

PART I — FINANCIAL INFORMATION
		Page
Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023	3
	Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023	5
	Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Six Months Ended June 30, 2024 and 2023	6
	Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023	10
	Notes to Unaudited Condensed Consolidated Financial Statements	11

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	43

Item 4.	Controls and Procedures	43

PART II — OTHER INFORMATION

Item 1.	Legal Proceedings	44

Item 1A.	Risk Factors	44

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44

Item 3.	Defaults Upon Senior Securities	44

Item 4.	Mine Safety Disclosures	44

Item 5.	Other Information	44

Item 6.	Exhibits	45

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)

	June 30,		December 31,
	2024		2023
ASSETS

Current Assets:
Cash and cash equivalents	$	275	$	591
Trade receivables, net of allowance for doubtful accounts of nil and $2 at June 30, 2024 and December 31, 2023, respectively.		2		7
Inventory, net of reserves of $818 at June 30, 2024 and December 31, 2023		632		632
Other current assets		112		163
Total current assets		1,021		1,393

Non-Current Assets:
Property and equipment, net		28		32
Operating lease right-of-use assets, net of amortization		185		227
Other assets		17		17
Total non-current assets		230		276

TOTAL ASSETS	$	1,251	$	1,669

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:
Accounts payable	$	2,143	$	1,991
Accounts payable, related parties		34		32
Accrued liabilities		840		1,068
Deferred revenue		748		424
Current portion of lease liability		99		91
Current portion of long-term debt, related parties		520		39
Short-term notes payable		112		59
Short-term convertible debt		94		1,105
Short-term convertible debt in default		1,130		-
Derivative liability at fair value		12		-
Total current liabilities		5,732		4,809

Long-Term Liabilities
Long-term lease liability		104		155
Long-term notes payable		59		-
Long-term debt, related parties		23		511
Total long-term liabilities		186		666

Total liabilities		5,918		5,475

COMMITMENTS AND CONTINGENCIES (Note 6)

Table of Contents

STOCKHOLDERS’ DEFICIT:

Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $286 at June 30, 2024 and December 31, 2023.		105			105
Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,049 at June 30, 2024 and December 31, 2023.		170			170
Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, 2.7 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $2,700 at June 30, 2024 and December 31, 2023.		439			439
Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.4 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $438 at June 30, 2024 and December 31, 2023.		159			159
Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $883 at June 30, 2024 and December 31, 2023.		834			834
Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.1 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,006 at June 30, 2024 and December 31, 2023.		838			838
Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $520 at June 30, 2024 and December 31, 2023.		475			475
Common stock, $0.001 par value; 500,000 shares authorized, 56,267 and 54,105 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively.		3,442			3,441
Additional paid-in capital		141,320			140,983
Treasury stock at cost		(132	)		(132	)
Accumulated deficit		(152,317	)		(151,118	)

Total stockholders’ deficit		(4,667	)		(3,806	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,251		$	1,669

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2024			2023			2024			2023

Sales - devices and disposables	$	-		$	44		$	6			66
Cost of goods sold		-			33			2			42
Gross profit		-			11			4			24

Operating expenses:
Research and development		222			66			275			73
Sales and marketing		69			61			142			134
General and administrative		364			1,389			600			2,166
Total operating expenses		655			1,516			1,017			2,373

Loss from operations		(655	)		(1,505	)		(1,013	)		(2,349	)

Other income (expenses):
Interest expense		(75	)		(69	)		(139	)		(134	)
Interest income		-			-			3			-
Change in fair value of derivative liability		(7	)		-			(7	)		5
Gain from extinguishment of debt		16			17			33			52
Other income (expenses)		12			-			12			-
Total other income (expense)		(54	)		(52	)		(98	)		(77	)

Loss before income taxes		(709	)		(1,557	)		(1,111	)		(2,426	)
Provision for income taxes		-			-			-			-

Net loss		(709	)		(1,557	)		(1,111	)		(2,426	)
Deemed dividend for warrant exchanges		-			-			-			(65	)
Preferred stock dividends		(49	)		(47	)		(88	)		(82	)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(758	)	$	(1,604	)	$	(1,199	)	$	(2,573	)

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)
Diluted	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

Weighted average shares outstanding
Basic		55,986			50,970			55,368			50,138
Diluted		55,986			50,970			55,368			50,138

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED JUNE 30, 2024
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2024		-	$	105		1	$	170		2	$	439		1	$	159
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2024		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock				Preferred Stock
	Series E				Series F				Series F2
	Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2024		1	$	834		1	$	838		-	$	475
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-
Net loss		-		-		-		-		-		-
Balance at June 30, 2024		1	$	834		1	$	838		-	$	475

					Additional
	Common Stock				Paid-In		Treasury			Accumulated
	Shares		Amount		Capital		Stock			Deficit				Total
Balance at March 31, 2024		55,614	$	3,441	$	141,218	$	(132	)	$	(151,559	)	$	(4,012	)
Issuance of common stock for payment of Series D preferred dividends		71		-		6		-			-			6
Issuance of common stock for payment of Series F-2 preferred dividends		72		-		7		-			-			7
Issuance of common stock for payment of interest		510		1		47		-			-			48
Issuance of warrants with debt		-		-		12		-			-			12
Stock-based compensation		-		-		30		-			-			30
Accrued preferred dividends		-		-		-		-			(49	)		(49	)
Net loss		-		-		-		-			(709	)		(709	)
Balance at June 30, 2024		56,267	$	3,442	$	141,320	$	(132	)	$	(152,317	)	$	(4,667	)

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED JUNE 30, 2023
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at March 31, 2023		-	$	105		1	$	170		2	$	439		1	$	159
Common stock warrants exercised		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Conversion of Series F preferred stock to common stock		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2023		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock					Preferred Stock
	Series E				Series F					Series F2
	Shares		Amount		Shares		Amount			Shares		Amount
Balance at March 31, 2023		1	$	834		1	$	858			3	$	475
Common stock warrants exercised		-		-		-		-			-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-			-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-			-		-
Conversion of Series F preferred stock to common stock		-		-		-		(20	)		-		-
Stock-based compensation		-		-		-		-			-		-
Accrued preferred dividends		-		-		-		-			-		-
Net loss		-		-		-		-			-		-
Balance at June 30, 2023		1	$	834		1	$	838			3	$	475

					Additional
	Common Stock				Paid-In			Treasury			Accumulated
	Shares		Amount		Capital			Stock			Deficit			Total
Balance at March 31, 2023		50,814	$	3,438	$	139,127		$	(132	)	$	(148,328	)	$	(2,855	)
Common stock warrants exercised		48		-		9			-			-			9
Issuance of common stock for payment of Series D preferred dividends		33		-		8			-			-			8
Issuance of common stock for payment of Series F-2 preferred dividends		36		-		9			-			-			9
Conversion of Series F preferred stock to common stock		80		-		20			-			-			-
Stock-based compensation		-		-		1,119			-			-			1,119
Accrued preferred dividends		-		-		(1	)		-			(47	)		(48	)
Net loss		-		-		-			-			(1,557	)		(1,557	)
Balance at June 30, 2023		51,011	$	3,438	$	140,291		$	(132	)	$	(149,932	)	$	(3,315	)

The accompanying notes are an integral part of these condensed consolidated statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2024
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2023		-	$	105		1	$	170		2	$	439		1	$	159
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Settlement of previously accrued professional fees through common stock issuance		-		-		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2024		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock				Preferred Stock				Preferred Stock
	Series E				Series F				Series F2
	Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2023		1	$	834		1	$	838		-	$	475
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-
Settlement of previously accrued professional fees through common stock issuance		-		-		-		-		-		-
Issuance of warrants with debt		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-
Net loss		-		-		-		-		-		-
Balance at June 30, 2024		1	$	834		1	$	838		-	$	475

					Additional
	Common Stock				Paid-In		Treasury			Accumulated
	Shares		Amount		Capital		Stock			Deficit			Total
Balance at December 31, 2023		54,105	$	3,441	$	140,983	$	(132	)	$	(151,118	)	$	(3,806	)
Issuance of common stock for payment of Series D preferred dividends		125		-		15		-			-			15
Issuance of common stock for payment of Series E preferred dividends		52		-		8		-			-			8
Issuance of common stock for payment of Series F preferred dividends		445		-		54		-			-			54
Issuance of common stock for payment of Series F-2 preferred dividends		236		-		27		-			-			27
Issuance of common stock for payment of interest		904		1		104		-			-			105
Settlement of previously accrued professional fees through common stock issuance		400		-		57		-			-			57
Issuance of warrants with debt		-		-		12		-			-			12
Stock-based compensation		-		-		60		-			-			60
Accrued preferred dividends		-		-		-		-			(88	)		(88	)
Net loss		-		-		-		-			(1,111	)		(1,111	)
Balance at June 30, 2024		56,267	$	3,442	$	141,320	$	(132	)	$	(152,317	)	$	(4,667	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2023
(unaudited, in thousands)

	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock
	Series C				Series C1				Series C2				Series D
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount
Balance at December 31, 2022		-	$	105		1	$	170		2	$	439		1	$	159
Common stock warrants exercised		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series D preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series E preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F preferred dividends		-		-		-		-		-		-		-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-		-		-		-		-		-		-
Conversion of Series E preferred stock to common stock		-		-		-		-		-		-		-		-
Conversion of Series F preferred stock to common stock		-		-		-		-		-		-		-		-
Conversion of Series F-2 preferred stock to common stock		-		-		-		-		-		-		-		-
Issuance of common stock for payment of interest		-		-		-		-		-		-		-		-
Stock-based compensation		-		-		-		-		-		-		-		-
Impact of warrant exchanges		-		-		-		-		-		-		-		-
Accrued preferred dividends		-		-		-		-		-		-		-		-
Net loss		-		-		-		-		-		-		-		-
Balance at June 30, 2023		-	$	105		1	$	170		2	$	439		1	$	159

	Preferred Stock					Preferred Stock					Preferred Stock
	Series E					Series F					Series F2
	Shares		Amount			Shares		Amount			Shares		Amount
Balance at December 31, 2022		1	$	839			1	$	880			3	$	489
Common stock warrants exercised		-		-			-		-			-		-
Issuance of common stock for payment of Series D preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series E preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series F preferred dividends		-		-			-		-			-		-
Issuance of common stock for payment of Series F-2 preferred dividends		-		-			-		-			-		-
Conversion of Series E preferred stock to common stock		-		(5	)		-		-			-		-
Conversion of Series F preferred stock to common stock		-		-			-		(42	)		-		-
Conversion of Series F-2 preferred stock to common stock		-		-			-		-			-		(14	)
Issuance of common stock for payment of interest		-		-			-		-			-		-
Stock-based compensation		-		-			-		-			-		-
Impact of warrant exchanges		-		-			-		-			-		-
Accrued preferred dividends		-		-			-		-			-		-
Net loss		-		-			-		-			-		-
Balance at June 30, 2023		1	$	834			1	$	838			3	$	475

					Additional
	Common Stock				Paid-In			Treasury			Accumulated
	Shares		Amount		Capital			Stock			Deficit			Total
Balance at December 31, 2022		48,596	$	3,437	$	138,090		$	(132	)	$	(147,359	)	$	(2,883	)
Common stock warrants exercised		1,120		1		230			-			-			231
Issuance of common stock for payment of Series D preferred dividends		59		-		14			-			-			14
Issuance of common stock for payment of Series E preferred dividends		26		-		8			-			-			8
Issuance of common stock for payment of Series F preferred dividends		233		-		53			-			-			53
Issuance of common stock for payment of Series F-2 preferred dividends		121		-		29			-			-			29
Conversion of Series E preferred stock to common stock		20		-		5			-			-			-
Conversion of Series F preferred stock to common stock		200		-		42			-			-			-
Conversion of Series F-2 preferred stock to common stock		60		-		14			-			-			-
Issuance of common stock for payment of interest		178		-		59			-			-			59
Stock-based compensation		400		-		1,683			-			-			1,683
Impact of warrant exchanges		-		-		65			-			(65	)		-
Accrued preferred dividends		-		-		(1	)		-			(82	)		(83	)
Net loss		-		-		-			-			(2,426	)		(2,426	)
Balance at June 30, 2023		51,011	$	3,438	$	140,291		$	(132	)	$	(149,932	)	$	(3,315	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)

	Six Months Ended
	June 30,
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,111	)	$	(2,426	)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense		1			2
Depreciation		5			5
Amortization of debt issuance costs and discounts		50			65
Stock-based compensation		60			1,683
Change in fair value of derivative liability		7			(5	)
Amortization of lease right-of-use-asset		42			37
Gain from forgiveness of debt		(33	)		(52	)
Other non-cash expenses		6			11
Change in operating assets and liabilities:
Accounts receivable		4			(3	)
Inventory		-			(25	)
Other current assets		52			46
Accounts payable and accrued liabilities		323			(173	)
Lease liabilities		(44	)		(38	)
Deferred revenue		324			(64	)
NET CASH USED IN OPERATING ACTIVITIES		(314	)		(937	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable		200			-
Payments of debt issuance costs		(17	)		-
Payments made on notes payable		(185	)		(213	)
Proceeds from warrant exercises		-			195
NET CASH USED IN FINANCING ACTIVITIES		(2	)		(18	)

NET CHANGE IN CASH		(316	)		(955	)

Cash at beginning of period		591			2,313

CASH AT END OF PERIOD	$	275		$	1,358

SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	$	21		$	47

SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:

Dividends on preferred stock	$	88	$	82
Deemed dividends for warrant exchanges	$	-	$	65
Warrants issued with debt	$	12	$	-
Beneficial conversion feature	$	6	$	-
Common stock issued for payment of interest	$	105	$	59
Common stock issued for payment of accrued dividends	$	104	$	105
Settlement of previously accrued professional fees through common stock issuance	$	57	$	-
Accrued payroll liability exchanged for promissory note	$	87	$	-
Conversion of Series E preferred shares into common stock	$	-	$	5
Conversion of Series F preferred shares into common stock	$	-	$	42

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION

Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2023 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2023. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of June 30, 2024 and December 31, 2023, and the consolidated results of operations and cash flows for the three and six-month periods ended June 30, 2024 and 2023 have been included.

The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of June 30, 2024, it had an accumulated deficit of approximately $152.1 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.

The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision maker is the Chief Executive Officer and acting Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas.

Table of Contents

Going Concern

The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

At June 30, 2024, the Company had a negative working capital of approximately $4.7 million, accumulated deficit of $152.3 million, and incurred a net loss including preferred dividends of $1.2 million for the six months then ended. Stockholders’ deficit totaled approximately $4.7 million at June 30, 2024, primarily due to recurring net losses from operations.

During the year ended December 31, 2023, the Company received $0.4 million of proceeds from warrant exercises. During the six months ended June 30, 2024, the Company received $0.2 million of proceeds from the issuance of promissory notes payable. The Company will need to continue to raise capital in order to provide funding for its operations and FDA/NMPA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications did not affect net loss, revenues or stockholders’ equity.

2. SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.

Accounting Standard Updates

A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.

Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

Concentrations of Credit Risk

The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was nil and $156,112 as of June 30, 2024 and December 31, 2023, respectively.

Table of Contents

Trade Receivables

Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of June 30, 2024 and December 31, 2023.

Inventory Valuation

All inventories are stated at the lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. Inventories consisted of the following as of June 30, 2024 and December 31, 2023:

	(in thousands)
	June 30,			December 31,
	2024			2023

Raw materials	$	1,360		$	1,360
Work-in-progress		46			46
Finished goods		44			44
Inventory reserve		(818	)		(818	)

Total inventory	$	632		$	632

The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Depreciation and amortization expense are included in general and administrative expense on the statements of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment consisted of the following as of June 30, 2024 and December 31, 2023:

Table of Contents

	(in thousands)
	June 30,			December 31,
	2024			2023

Equipment	$	951		$	951
Software		634			634
Furniture and fixtures		17			17
Leasehold improvements		12			12

Subtotal		1,614			1,614
Less accumulated depreciation		(1,586	)		(1,582	)
Property, equipment and leasehold improvements, net
	$	28		$	32

Depreciation expense related to property and equipment for the three and six months ended June 30, 2024 and 2023 was not material.

Debt Issuance Costs

Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.

Patent Costs (Principally Legal Fees)

Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three and six months ended June 30, 2024 and 2023.

Leases

A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.

Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities.

The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 6 – “Commitments and Contingencies.”

Table of Contents

Accrued Liabilities

Accrued liabilities as of June 30, 2024 and December 31, 2023 are summarized as follows:

	(in thousands)
	June 30, 2024		December 31, 2023

Compensation	$	356	$	401
Professional fees		95		216
Interest		143		188
Vacation		29		27
Preferred dividends		210		228
Other accrued expenses		7		8
Total	$	840	$	1,068

Stock Subscription Payable

Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.

Revenue Recognition

ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. The application of the core principle in ASC 606 is carried out in five steps:

	·	Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

	·	Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

	·	Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

	·	Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

	·	Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

Table of Contents

The Company’s revenues do not require significant estimates or judgments and are recognized when control of the promised goods or services is transferred to the Company’s customers, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. Revenue is measured as the amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company does not offer returns, discounts, loyalty programs or other sales incentive programs that are material to revenue recognition. The Company is not party to contracts that include multiple performance obligations or material variable consideration.

Contract Balances

The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. Deferred revenue totaled $747,780, $424,225, and $509,101 as of June 30, 2024, December 31, 2023 and December 31, 2022, respectively.

Significant Customers

As of June 30, 2024, trade receivables of $2,047 (net of the allowance for credit losses of $450) were attributed to one customer. As of December 31, 2023, accounts receivable of $7,442 (net of the allowance for credit losses of $1,500) were attributed to two customers.

Research and Development

Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.

Income Taxes

The provision for income taxes is determined in accordance with ASC 740, “Income Taxes”. The Company provides for income taxes based on enacted tax law and statutory tax rates at which items of income and expense are expected to be settled in our income tax return. Certain items of revenue and expense are reported for Federal income tax purposes in different periods than for financial reporting purposes, thereby resulting in deferred income taxes. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company has filed for an extension for its 2023 federal and state corporate tax returns. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At June 30, 2024, the Company had approximately $66.4 million of net operating losses carryforward available, $3.8 million of which will expire on December 31, 2024. The remaining net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses.

The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.

Table of Contents

Warrants

The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes or binomial option pricing models.

Stock Based Compensation

The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “Compensation – Stock Compensation”, which requires fair value measurement on the grant date and recognition of compensation expense for all stock-based payment awards made to employees and directors. The Company determines the fair value of stock options using the Black-Scholes model. The fair value of restricted stock awards is based upon the quoted market price of the shares of common stock on the date of grant. The fair value of stock-based awards is expensed over the requisite service periods of the awards. The Company accounts for forfeitures of stock-based awards as they occur.

The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.

During the six months ended June 30, 2024, the Company recognized $29,673 of expense related to stock options and $30,932 of expense for warrants issued to a director. During the six months ended June 30, 2023, the Company recognized $206,306 of expense related to stock options, $116,000 of expense for stock issued to a director and $1,361,143 of expense for warrants issued to consultants and executives.

Derivatives

The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

Fair Value Measurements

ASC 820, “Fair Value Measurements and Disclosures,” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Table of Contents

	·	Level 1: Quoted prices for identical assets or liabilities in active markets that the Company can access at the measurement date.

	·	Level 2: Significant other observable inputs other than level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

	·	Level 3: Significant unobservable inputs that reflect the Company’s judgment about the assumptions that market participants would use in pricing an asset or liability.

An asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820:

	·	Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

	·	Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

	·	Income approach: Techniques to convert future amounts to a single present value amount

The Company believes its valuation methods are appropriate and consistent with other market participants, however the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

3. STOCKHOLDERS’ DEFICIT

Common Stock

The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of June 30, 2024 and December 31, 2023, 56,266,661 and 54,105,101 shares of common stock were issued and outstanding, respectively.

During the six months ended June 30, 2024, the Company issued 2,161,560 shares of common stock, as summarized below:

	Number of Shares
Issuance of common stock for payment of Series D preferred dividends		125,505
Issuance of common stock for payment of Series E preferred dividends		52,332
Issuance of common stock for payment of Series F preferred dividends		444,621
Issuance of common stock for payment of Series F-2 preferred dividends		235,544
Issuance of common stock for payment of interest		903,558
Issuance of common stock to consultants		400,000
Total common stock issued during the six months ended June 30, 2024		2,161,560

Summary table of common stock transactions:
Shares outstanding at December 31, 2023		54,105,101
Common shares issued during the six months ended June 30, 2024		2,161,560
Shares outstanding at June 30, 2024		56,266,661

Table of Contents

Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock with a $0.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions.

Series C Convertible Preferred Stock

The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C Preferred Stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At June 30, 2024 and December 31, 2023, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C Preferred Stock would convert into approximately 2,000 shares of the Company’s common stock; for a total of 572,000 shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt.

Holders of the Series C Preferred Stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of June 30, 2024 and December 31, 2023. Upon conversion of the Series C Preferred Stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At June 30, 2024 and December 31, 2023, the “make-whole payment” for a converted share of Series C Preferred Stock would convert to 200 shares of the Company’s common stock.

The Series C Preferred Stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends.

Series C1 Convertible Preferred Stock

The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049.25 shares were issued and outstanding at June 30, 2024 and December 31, 2023. The C1 Convertible Preferred Stock has a conversion price of $0.50 per share, such that each share would convert into approximately 2,000 shares of the Company’s common stock, for a total of 2,098,500 shares of common stock.

The Series C1 Preferred Stock has terms that are substantially the same as the Series C Preferred Stock, except that the Series C1 Preferred Stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C Preferred Stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt.

Series C2 Convertible Preferred Stock

On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Convertible Preferred Stock, including the chairman of the Company’s board of directors, the former Chief Operating Officer (now the Chief Executive Officer) and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Convertible Preferred Stock. In total, for 3,262.25 shares of Series C1 Convertible Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Convertible Preferred Stock.

Table of Contents

At June 30, 2024 and December 31, 2023, there were 2,700 shares outstanding, each with a conversion price of $0.50 per share, such that each share of Series C2 preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total of 5,400,000 common shares.

The terms of the Series C2 Convertible Preferred Stock are substantially the same as the Series C1 shares, except that (i) shares of Series C1 Convertible Preferred Stock were not convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Convertible Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Convertible Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing.

Series D Convertible Preferred Stock

The board designated 6,000 shares of preferred stock as Series D Preferred Stock, 438 of which remained outstanding as of June 30, 2024 and December 31, 2023. On January 8, 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer (now the Chief Executive Officer) and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 shares of common stock, 1,526,000 common stock warrants exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 shares of common stock. The Series D Preferred Stock have cumulative dividends at the rate per share of 10% per annum. Each share of Series D Preferred Stock has a par value of $0.001 per share and a stated value equal to $750.

Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

During the six months ended June 30, 2024, the Company issued 125,505 shares of common stock for the payment of accrued Series D Preferred Stock dividends. As of June 30, 2024, and December 31, 2023, the Company had accrued dividends for the Series D Preferred Stock of $8,360.

Series E Convertible Preferred Stock

The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 883 of which remained outstanding as of June 30, 2024 and December 31, 2023. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a stated value equal to $1,000, subject to the increase set forth in its Certificate of Designation.

Table of Contents

Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, at the option of the Company, shares of common stock.

During the six months ended June 30, 2024, the Company issued 52,332 shares of common stock for payment of accrued Series E Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends of $57,592 and $30,272 for the Series E Preferred Stock, respectively.

Series F Convertible Preferred Stock

The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,006 of which remained outstanding as of June 30, 2024 and December 31, 2023. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 shares of common stock. The Series F Preferred Stock is entitled to cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F Preferred Stock is $1,000.

Each share of Series F Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred Stock is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate stated value then outstanding plus accrued but unpaid dividends.

During the six months ended June 30, 2024, the Company issued 444,621 shares of common stock for the payment of annual Series F Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends for Series F preferred shares of $15,761 and $46,108, respectively.

Series F-2 Convertible Preferred Stock

The Company was oversubscribed for its Series F Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Preferred Stock with substantially the same terms as the Series F Preferred Stock. The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 520 of which were issued and outstanding as of June 30, 2024 and December 31, 2023. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors. In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred share is convertible into 4,000 shares of common stock. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F-2 Preferred Stock is $1,000.

Each share of Series F-2 Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred Stock, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

During the six months ended June 30, 2024, the Company issued 235,544 shares of common stock for the payment of annual Series F-2 Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends for Series F-2 preferred shares of $7,918 and $23,579, respectively.

Table of Contents

Warrants

The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the six months ended June 30, 2024 and 2023:

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2023		28,584,580		$	0.50
Warrants issued		1,000,000			0.30
Warrants expired		(761,500	)		0.37
Outstanding, June 30, 2024		28,823,080		$	0.50

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2022		35,586,980		$	0.46
Warrants issued		5,873,750			0.25
Warrants exchanged		(1,025,000	)		0.25
Warrants expired		(9,478,200	)		0.30
Warrants exercised		(973,750	)		0.20
Outstanding, June 30, 2023		29,983,780		$	0.49

During the six months ended June 30, 2024 and 2023, the Company issued 900,000 warrants to Richard Blumberg, a related party, pursuant to a consulting agreement. See Note 6, “Commitments and Contingencies” for additional information.

During the six months ended June 30, 2024, the Company issued 100,000 warrants in conjunction with the issuance of a $100,000 note payable to an unaffiliated third party. See Note 7, “Notes Payable” for additional details on the note payable. Management estimated the fair value of the warrants issued utilizing the Black-Scholes Option Pricing model with the following assumptions:

Expected term (years)	4.0
Volatility	389.2	%
Risk-free interest rate	4.4	%
Dividend yield	0.0	%

On May 14, 2023, the Compensation Committee of the Company’s Board of Directors approved the issuance of 4,000,000 common stock warrants to Mark Faupel, upon his appointment to the Company’s Board as President and Chief Executive Officer on March 10, 2023. The warrants, which have a strike price of $0.25, are fully vested and will expire on May 13, 2028. During the six months ended June 30, 2023, the Company recorded approximately $679,959 of stock-based compensation expense attributed to the warrants.

Table of Contents

On May 14, 2023, the Compensation Committee of the Company’s Board of Directors also approved the issuance of 4,000,000 common stock warrants to Mark Faupel, 2,500,000 of which will be vested upon receipt by the Corporation of an Approval Letter from the U.S. Food and Drug Administration for the LuViva Advanced Cervical Scan and 1,500,000 of which will be vested upon receipt by the Corporation of an Approval Letter or equivalent from the Chinese National Medical Products Administration for the LuViva Advanced Cervical Scan. The warrants, which have a strike price of $0.40, will expire five years after they are exercisable with a maximum term of 10 years from issuance. As of June 30, 2023, the Company has concluded it is not probable that the performance conditions related to the warrants will be achieved, and as a result no compensation expense related to the warrants has been recorded.

During the six months ended June 30, 2023, the Company entered into various agreements with holders of the Company’s $0.25 strike price warrants, pursuant to which each holder separately agreed to exchange 1,025,000 common stock warrants with a strike price of $0.25 for 973,750 common stock warrants with a strike price of $0.20. The Company received approximately $194,750 from the holders for the exercise of the 973,750 warrants. The Company measured the effect of the exchange as the excess of fair value of the exchanged instruments over the fair value of the original instruments and recorded a deemed dividend of approximately $65,296.

During the six months ended June 30, 2023, management estimated the fair value of the warrants issued utilizing the Black-Scholes Option Pricing model with the following weighted-average assumptions:

Expected term (years)	3.9
Volatility	290.6	%
Risk-free interest rate	3.7	%
Dividend yield	0.0	%

4. STOCK OPTIONS

The Company’s Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The aggregate number of common shares that may be issued or reserved pursuant to stock option or other awards under the plan may not exceed 2,500,000 common shares.

During the six months ended June 30, 2024 and 2023, the Company recognized expense for stock options of $29,673 and $206,306, respectively. There was no stock option activity during the six months ended June 30, 2024.

On February 10, 2023, the Company granted 925,000 stock options to employees, executives and directors of the Company. The stock options, which have exercise prices of $0.2629, will expire on February 9, 2033. One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023.

On March 7, 2023, the Company granted 100,000 stock options, which have exercise prices of $0.27 and will expire on March 6, 2033, to Alan Grujic, upon appointing him to the Board of Directors. One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023.

Table of Contents

The following tables summarize the Company’s stock option activity and related information for the six months ended June 30, 2024 and 2023:

	Number of Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2023		2,338,636	$	0.41	6.5 years	$	-
Options outstanding as of June 30, 2024		2,338,636	$	0.41	6.1 years	$	-
Options exercisable as of June 30, 2024		1,980,114	$	0.43	5.6 years	$	-

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2022		1,500,000		$	0.49	7.5 years	$	-
Options granted		1,025,000		$	0.26
Options forfeited		(186,364	)	$	0.31
Options outstanding as of June 30, 2023		2,338,636		$	0.41	7.1 years	$	-
Options exercisable as of June 30, 2023		1,755,114		$	0.45	6.2 years	$	-

The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of June 30, 2024 and the exercise price, multiplied by the number of options. As of June 30, 2024, there was $94,578 of unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.75 years. The weighted-average fair value of awards granted was nil and $0.26 during the six months ended June 30, 2024 and 2023, respectively.

The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The Black-Scholes option pricing model and the following weighted-average assumptions were used to estimate the fair value of awards granted during the six months ended June 30, 2023:

Expected term (years)	10.0
Volatility	366.4	%
Risk-free interest rate	3.8	%
Dividend yield	0.00

On March 3, 2023, Dr. Gene Cartwright retired from his position as President and Chief Executive Officer of the Company and as a member of the Board. Upon his departure, Mr. Cartwright forfeited 186,364 unvested stock options. On May 2, 2023, the Company’s Board of Directors approved an extension of the expiration date of Mr. Cartwright’s vested options to June 1, 2025. Management measured the modified stock option award using the Black-Scholes option pricing model and recorded expense of $59,216 during the six months ended June 30, 2023, representing the excess fair value of the modified award over the original award. Management estimated the fair value of the modified award using the Black-Scholes option pricing model and the following assumptions:

Expected term (years)	2.0
Volatility	182.8	%
Risk-free interest rate	4.0	%
Dividend yield	0.0	%

5. LITIGATION AND CLAIMS

From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year.

As of June 30, 2024, and December 31, 2023, there was no accrual recorded for any potential losses related to pending litigation.

Table of Contents

6. COMMITMENTS AND CONTINGENCIES

Operating Leases

Our corporate offices, which also comprise our administrative, research and development, marketing and production facilities, are located on a 12,835 square foot leased property. Total operating lease cost recognized for this lease was unchanged from the prior period and was $27,351 and $54,702 for the three and six months ended June 30, 2024, respectively. The below table presents total operating lease right-of-use assets and lease liabilities as of June 30, 2024 and December 31, 2023:

	(in thousands)
	June 30,		December 31
	2024		2023
Operating lease right-of-use assets	$	185	$	227
Operating lease liabilities	$	203	$	246

The table below presents the maturities of operating lease liabilities as of June 30, 2024:

	(in thousands)
	Operating
	Lease Payments
2024 (remaining)		58
2025		118
2026		50
Total future lease payments		226
Less: discount		(23	)
Total lease liabilities	$	203

The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities as of June 30, 2024 and December 31, 2023

	(in thousands)
	June 30, 2024			December 31, 2023
Weighted average remaining lease term (years)		1.9			2.4
Weighted average discount rate		11.4	%		11.4	%

Related Party Contracts

On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee).

Table of Contents

On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each cervical guide that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company).

On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company agreed to issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the scheduled issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020. As of June 30, 2024, unrecognized consulting expense associated with the agreement was nil and 2,500,000 of the warrants had been issued, of which 1,750,000 were issued to Mr. Blumberg and 750,000 were issued to non-related parties.

During the six months ended June 30, 2023, the Company entered into an agreement with Mr. Blumberg to exchange 875,000 of the outstanding warrants for 831,250 warrants with a strike price of $0.20, which were exercised during the first quarter of 2023.

On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for the following: (1) 3,600,000 3-year warrants with exercise prices ranging from $0.30 - $0.60, and (2) 1,600,000 common stock shares. On September 30, 2021, the Company and Mr. Blumberg entered into an amended agreement, pursuant to which issuance of the warrants and common shares became predicated on the Company obtaining financing or a series of financings resulting in minimum receipts of at least $1.0 million. Upon receipt of the funds, the Company agreed to issue the common shares and warrants owed to Mr. Blumberg in four equal tranches, to be issued every six months, beginning six months after the financing transaction. On November 11, 2022, the Company and Mr. Blumberg entered into an amended agreement, upon which the exercise prices of the warrants were changed to $0.30. The Company estimated the fair value of the modified warrants using the Black-Scholes option pricing model and the following assumptions:

Expected term (years)	3.0
Volatility	108.7	%
Risk-free interest rate	4.3	%
Dividend yield	0.0	%

During the six months ended June 30, 2024 and 2023, the Company issued 900,000 warrants to Mr. Blumberg, pursuant to the agreement, and recognized expense of nil and $590,840, respectively. Total unrecognized expense for the warrants was nil as of June 30, 2024. During the six months ended June 30, 2024 and 2023, the Company recognized $7,425 and $111,833 of expense for the shares of common stock due to Mr. Blumberg, respectively. As 400,000 shares had not been issued as of June 30, 2024, the Company estimated the total amount of expense for the future issuances using the closing price of the Company’s stock as of June 30, 2024.

On August 24, 2022, the Company entered into an agreement with Ironstone Capital Corp. and Alan Grujic (the “Advisory Group”) whereby the Advisory Group agreed to perform marketing and investor relations services over a term of twelve months, commencing on the closing of a financing of at least $2.5 million. In consideration for these services, the Company issued 800,000 warrants (“first tranche of warrants”) with an exercise price of $0.50 to Mr. Grujic, which were due within 10 business days of closing the financing transaction (the “Transaction”) that took place in September 2022. In the event the Company’s 20 trading day variable weighted average price (“VWAP”) exceeds $1.00 within one year of the closing of the financing, the Company would have issued 600,000 warrants (“second tranche of warrants”) with an exercise price of $0.75 to Mr. Grujic. In the event the Company’s 20 trading day VWAP exceeds $1.50 within two years of the closing of the financing, the Company will issue an additional 600,000 warrants (“third tranche of warrants”) to Mr. Grujic. Once issued, the warrants vest immediately and will expire two years from the date of issuance. If the Company’s U.S. clinical study is not completed and filed with the U.S. FDA or if the Chinese NMPA (formerly Chinese FDA) approval is not granted by each due date for reaching each respective pricing milestone, then the due date for reaching each milestone shall be extended by six months. As of June 30, 2024, the deadline to achieve the stock price of $1.50 has passed and the second tranche warrants will therefore not be issued.

Table of Contents

Pursuant to the agreement, the Company also agreed to pay the Advisory Group $2,000 per month for 12 months, starting the month after the closing of the Transaction. Subsequently, the agreement was amended to extend the term of the agreement to September of 2024.

The Company estimated the fair value of the first tranche warrants issued in September 2022 using the Black-Scholes option pricing model with the following assumptions:

Expected term (years)	2.0
Volatility	173.0	%
Risk-free interest rate	3.4	%
Dividend yield	0.0	%

Expense related to the first tranche of warrants was recognized in prior years. Unrecognized expense related to the first tranche warrants was nil as of June 30, 2024.

The Company estimated the fair value of the second tranche warrants using the Binomial Lattice model with the following assumptions:

Expected term (years)	1.0
Volatility	144.4	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

The Company recognized expense for the second tranche of warrants of nil and $29,706 during the three months ended June 30, 2024 and 2023, respectively. The Company recognized expense for the second tranche of warrants of nil and $59,412 during the six months ended June 30, 2024 and 2023, respectively. Unrecognized expense for the third tranche of warrants was nil as of June 30, 2024.

The Company estimated the fair value of the third tranche warrants using the Binomial Lattice model with the following assumptions:

Expected term (years)	2.0
Volatility	172.1	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

The Company recognized expense for the third tranche of warrants of $15,466 during the three months ended June 30, 2024 and 2023. The Company recognized expense for the third tranche of warrants of $30,932 during the six months ended June 30, 2024 and 2023. Unrecognized expense for the third tranche of warrants was $10,311 as of June 30, 2024.

Other Commitments

On July 24, 2019, the Company agreed to grant Shandong Yaohua Medical Instrument Corporation (“SMI”) (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the terms and conditions described below.

Table of Contents

First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 shares of common stock. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides, then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions.

On August 12, 2021, the Company executed an amendment to its agreement with SMI. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. On March 3, 2023, the Company entered into a third amendment with SMI pursuant to which the Company extended the deadline for SMI to achieve commercialization of LuViva in China to April 30, 2024.

On February 17, 2024, the Company entered into a fourth amendment to the agreement with SMI. Under the terms of the amended agreement, SMI agreed to pay the Company $531,100 on or prior to March 15, 2024. On March 18, 2024, SMI, through SMI’s authorized distribution partner, initiated a wire payment of $330,000 in partial satisfaction of $531,100 owed to the Company. The payment was received by the Company on March 20, 2024. As the full payment was not received by March 15, 2024, the Company had the right to terminate the agreement with two weeks’ notice to SMI, however the Company did not exercise this option.

The amended agreement also provides for a timeline for the Company to deliver inventory during 2024, including LuViva devices and components, as well as approximately 1,640,000 RFID chips. In consideration, SMI agreed to pay a total of $4.4 million during 2024, including the payment due on March 15, 2024.

On March 27, 2024, the parties entered into a Standstill Agreement (the “Standstill Agreement”). The parties agreed that SMI will make a nonrefundable payment of $100,000 to the Company prior to March 31, 2024. In exchange, the Company will not initiate any legal proceedings, including but not limited to filing a lawsuit, obtaining a judgement, or enforcing any security interest, as related to the March shortfall in payments of $201,100, until April 30, 2024. Upon paying $100,000, SMI will have the option to extend the Standstill Agreement until June 15, 2024 by making a nonrefundable payment to the Company of $150,000. One additional payment of $150,000 may be made to extend the standstill rights until July 30, 2024, if mutually agreed upon. If SMI is unable to make the payments pursuant to the Standstill Agreement, the Company agreed to seek loans on behalf of SMI to cover the payments. SMI agreed to reimburse the Company for these loans along with all expenses associated with them within three months of the loans being issued as long as the loans are used solely for (1) parts for LuViva devices to be used by SMI for marketing and promotional activities, or (2) labor or consulting fees connected to providing parts, assemblies of devices or disposables to SMI. Additionally, SMI confirmed its commitment to make payments to GTI of at least $4.0 million during 2024 and as part of this commitment will make payments of $200,000 and $500,000 by the end of May 2024 and July 2024, respectively, to ensure that the program commercialization proceeds according to schedule.

On April 26, 2024, the parties extended the Standstill Agreement (“Standstill Extension”) until July 30, 2024, contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545. The other terms from the Amendment and Standstill Agreement remained intact.

The Company and SMI executed an extension to the Standstill Agreement (the “Second Standstill Extension”) subsequent to June 30, 2024. Please see Note 12, “Subsequent Events” for details.

Contingencies

The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

Table of Contents

7. NOTES PAYABLE

On June 28, 2024, the Company issued a promissory note totaling $100,000 to an unaffiliated third party. The promissory note matures on January 1, 2025 and will accrue total interest of $10,000. Monthly payments of $20,000 are due on the note, beginning August 1, 2024 until December 1, 2024, while the interest payment is due on or before January 1, 2025. The promissory note may be prepaid in full or in part without penalty or premium. The holder of the promissory note also received 100,000 common stock purchase warrants, which will have an exercise price of $0.25 and will expire on July 1, 2028. The warrants, which had an estimated fair value of $11,998, were recorded as a discount on the note payable.

On April 15, 2024, the Company entered into an exchange agreement with a former employee, whereby the former employee agreed to exchange outstanding amounts due to him for deferred compensation in the amount of $81,768 for an $87,162 promissory note dated April 15, 2024. Beginning on May 5, 2024, monthly payments of $2,000 are due on the note until its maturity date. The promissory note, which accrues interest at a rate of 6% per annum, matures on May 5, 2028. The total balance of the promissory note was $83,162 as of June 30, 2024, of which $24,000 is presented in “Short-term notes payable” on the consolidated balance sheets and $59,162 is included in “Long-term notes payable.”

On July 4, 2023, the Company entered into a premium finance agreement to finance its insurance policies totaling $129,073. Monthly payments of $12,041 are due on the note, including interest incurred at a rate of 7.9%. The note, which matured on May 4, 2024, had an outstanding balance of nil and $59,422 as of June 30, 2024 and December 31, 2023, respectively.

The following table summarizes short-term notes payable (in thousands):

	Short-term notes payable
	June 30, 2024			December 31, 2023
Short-term promissory note	$	100		$	-
Current portion of long-term promissory note		24			-
Premium Finance (insurance)		-			59
Debt Discount		(12	)		-
Short-term notes payable	$	112		$	59

8. CONVERTIBLE DEBT

10% Senior Unsecured Convertible Debenture

On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which matured on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into shares of common stock at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit included 1,000 common stock warrants with an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into shares of common stock, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into shares of common stock at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the shares of common stock is $1.50 per share of common stock or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering shares of common stock to the holders of Convertible Debentures at a deemed price of $0.50 per share of common stock that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures.

Table of Contents

At June 30, 2024 and December 31, 2023, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total accrued interest was $24,860 and $58,494, respectively. After the May 17, 2024 maturity date, the interest rate increased to the default rate of 18.0%. The bond payable discount and unamortized debt issuance costs as of June 30, 2024 and December 31, 2023 are presented below (in thousands):

	Senior Secured Convertible Debenture
	June 30, 2024		December 31, 2023
10% Senior Unsecured Convertible Debentures	$	1,130	$	1,130
Unamortized debt issuance costs		-		(12	)
Debt Discount		-		(38	)
Senior Unsecured Convertible Debenture	$	1,130	$	1,080

As of June 30, 2024, the balance of the Senior Unsecured Convertible Debenture is included in “Short-term convertible notes payable in default” within the condensed consolidated balance sheets. As of December 31, 2023, the balance of the Senior Unsecured Convertible Debenture is included in “Short-term convertible notes payable” within the condensed consolidated balance sheets.

1800 Diagonal Lending Note

On June 11, 2024, the Company entered into a securities purchase agreement and contingently convertible note with 1800 Diagonal Lending LLC (“Diagonal Lending”). The convertible note issued to Diagonal Lending had a total principal balance of $100,050 and an original issue discount of $13,050. The note, which will accrue total interest of $14,007, will mature on April 15, 2025. A payment of $57,029 is due on the note on December 15, 2024. The remaining balance due, including accrued interest, will be paid in monthly payments of $14,257 from January 15, 2025 through April 15, 2025. The note may be prepaid within 120 days of issuance for a discount of 2.0 -3.0 % of the principal and accrued interest due. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note will become immediately due and payable in an amount equal to 150.0% times the sum of the then outstanding principal, accrued interest and default interest.

In an event of default, the unpaid portion of the note and accrued interest is convertible into shares of common stock at a conversion rate equal to the variable conversion price. The variable conversion price is equal to the lowest closing price of our common stock during the ten days prior to the conversion date multiplied by 65.0%. The Company assessed this embedded conversion feature and determined that it is not considered clearly and closely related to the host note, and therefore meets the definition of a derivative. Therefore, this embedded conversion feature is required to be bifurcated from the note and accounted for separately as a derivative liability. The Company estimated the fair value of the combined derivative liability as of June 11, 2024, which was recorded as a liability and as a discount net against the subordinated convertible notes. The Company is required to remeasure the combined derivative liability to its then fair value at each subsequent balance sheet date, through an adjustment to current earnings (see Note 11 for further details on the Company’s fair value measurement).

Table of Contents

At June 30, 2024, the balance due on the note was $100,000 and total accrued interest was $1,166. The note payable discount, unamortized debt issuance costs and unamortized debt discount (including the beneficial conversion feature) as of June 30, 2024 and December 31, 2023 is presented below (in thousands):

	June 30, 2024			December 31, 2023
Short-term convertible promissory note	$	100		$	-
Unamortized debt issuance costs		(4	)		-
Debt Discount		(12	)		-
Beneficial conversion feature		(5	)		-
1800 Diagonal Lending Convertible Note	$	79		$	-

Auctus Convertible Note

On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus Fund, LLC (“Auctus’). The convertible note issued to Auctus was for a total of $2.4 million. The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied.

On September 1, 2022, the Company agreed to exchange certain debt and equity owned by Auctus pursuant to an Exchange Agreement between the Company and Auctus (the “Exchange Agreement”). Immediately prior to the Exchange Agreement, Auctus held $1,228,183 of debt, including an early prepayment penalty of $350,000, default premiums of $281,256, and $91,555 in interest payable. Auctus agreed to reduce the amount owed to $710,911 and to revert the May 27, 2020 note to its original term. Additionally, Auctus agreed to exchange 8,775,000 warrants that were priced between $0.15 and $0.20 and the $350,000 prepayment penalty for 3,900,000 shares of common stock, warrants to purchase 3,900,000 shares of common stock at $0.50 per share and warrants to purchase 3,900,000 shares of common stock at $0.65 per share (the “Exchange”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. During 2024, Auctus agreed to apply the payments to the principal portion of the debt before applying the funds to the accrued interest. As a result, management has reclassified a portion of the current and prior period outstanding debt to the accrued interest as described below.

The total outstanding balance of the convertible note was $15,000 and $25,000 as of June 30, 2024 and December 31, 2023, respectively. The balances are included within “Short-term convertible notes payable” on the condensed consolidated balance sheets. Total accrued interest on the Auctus convertible note was $115,646 and $121,995 as of June 30, 2024 and December 31, 2023, respectively.

9. RELATED PARTY DEBT

On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum.

Table of Contents

On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement. Pursuant to this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement.

On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, the maturity date was February 18, 2023, and the interest rate was 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, the maturity date was February 18, 2023, and the interest rate was 6.0%. Additionally, the Company exchanged $100,000 and $85,000 of the balances owed to Dr. Cartwright and Dr. Faupel for 100 and 85 shares of Series F-2 Preferred Stock, respectively.

On February 18, 2023, the Company amended the terms of the promissory notes held by Mark Faupel and Gene Cartwright. Under the terms of the new agreements, the promissory notes will mature on February 18, 2025.

The tables below summarize the outstanding balance of long-term debt owed to Dr. Faupel and Dr. Cartwright (in thousands):

For Dr. Faupel:

Salary	$	134
Bonus		20
Vacation		95
Interest on compensation		67
Loans to Company		196
Interest on loans		149
Total outstanding prior to exchange		661

Amount forgiven in prior years		(454	)
Amount exchanged for Series F-2 Preferred Stock		(85	)
Total interest accrued through December 31, 2023		57
Balance outstanding at December 31, 2023	$	179

Interest accrued through June 30, 2024		5
Balance outstanding at June 30, 2024	$	184

Table of Contents

For Dr.Cartwright

Salary	$	337
Bonus		675
Loans to Company		528
Interest on loans		81
Total outstanding prior to exchange		1,621

Amount forgiven in prior years		(1,302	)
Amount exchanged for Series F-2 Preferred Stock		(100	)
Total interest accrued through December 31, 2023		93
Payments on outstanding debt		(25	)
Balance outstanding at December 31, 2023	$	287

Interest accrued through June 30, 2024		7
Balance outstanding at June 30, 2024	$	294

On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Stock (convertible into 200,000 shares of common stock), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,600 for four years, with the first payment due on March 15, 2022. The effective interest rate of the note is 6.18%.

During the three and six months ended June 30, 2024, Mr. Fowler forgave $16,401 and $33,060 of the outstanding balance of deferred compensation, respectively. During the three and six months ended June 30, 2023, Mr. Fowler forgave $17,450 and $35,171 of the outstanding balance of deferred compensation, respectively. As of June 30, 2024, Mr. Fowler may forgive up to $96,276 of the remaining deferred compensation if the Company complies with the repayment plan described above. The reductions in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of June 30, 2024 and December 31, 2023, the outstanding principal amount owed on the note was $63,731 and $82,945, respectively.

Future debt obligations at June 30, 2024 for debt owed to related parties is as follows:

Year	Amount (in thousands)
2024 (remaining)		21
2025		519
2026		3
Total	$	543

10. INCOME (LOSS) PER SHARE OF COMMON STOCK

Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year.

Table of Contents

Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series C-1, Series C-2, Series D, Series E, Series F and Series F-2 convertible preferred stock, convertible debt, convertible preferred dividends, warrants and stock options convertible into common stock shares.

During a period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt and preferred stock are anti-dilutive. For the three and six months ended June 30, 2024 and 2023, all stock options, convertible preferred stock, convertible debt and warrants were anti-dilutive and were therefore excluded from the computation of diluted loss per share. At June 30, 2024 and 2023, these instruments were convertible into 53,674,649 and 54,482,496 common shares, respectively.

The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data):

	June 30,
	2024			2023

Net loss		(1,199	)		(2,573	)
Basic weighted average number of shares outstanding		55,368			50,138
Net loss per share (basic)		(0.02	)		(0.05	)
Diluted weighted average number of shares outstanding		55,368			50,138
Net loss per share (diluted)		(0.02	)		(0.05	)

11. FAIR VALUE MEASUREMENTS

The convertible notes payable derivative liability is considered a Level 3 measurement, due to the significant unobservable inputs in the valuation, which are based on a forecast of the Company’s future stock performance and, as the note payable is contingently convertible upon an event of default, management’s estimate of the likelihood and timing of conversion.

Based on the terms and provisions of the Diagonal Lending note payable, management built a pricing simulation that predicts the Company’s future stock prices using historical volatility. Our model is designed to utilize the Company’s best estimates of the timing and likelihood of a conversion of the note payable to calculate the variable conversion price as of the future conversion date.

The key inputs to the valuation model that was utilized to estimate the fair value of the bifurcated conversion option included:

	·	The forecasted future stock prices were determined using historical stock prices and the Company’s equity volatility.
	·	The expected conversion price was determined using the forecast and the contractual term of the convertible note agreement.
	·	The probability of an event of default and timing of a future conversion are based on management’s best estimate of the future settlement of the convertible note.

Table of Contents

The following tables present the fair value of the bifurcated conversion option:

	Fair Value at June 30, 2024 (in thousands)
	Level 1		Level 2		Level 3		Total

Derivative liability/bifurcated conversion option in connection with Diagonal Lending $100,050 promissory note		-		-		13		13

Total short-term liabilities at fair value	$	-	$	-	$	13	$	13

Derivative financial instruments and changes thereto recorded in the six months ended June 30, 2024 and 2023 include the following:

	Six Months Ended June 30,
	2024		2023

Balance, beginning of period	$	-	$	(5	)
Inception of derivative liability		5
Change in fair value during the period		7		5

Balance, end of period	$	12	$	-

12. SUBSEQUENT EVENTS

Issuances of Promissory Notes and Related Warrants

On July 22, 2024, we issued a $62,100 convertible promissory note to Diagonal Lending. The convertible promissory note, which had an original issue discount of $8,100, will mature on May 30, 2025 and will accrue total interest of $8,694. A payment of $35,397 will be due on January 30, 2025. The remaining balance, including the accrued interest, will be paid in monthly installments of $8,849 beginning February 28, 2024 and ending on the maturity date. The remaining terms of the convertible promissory note are identical to the June 11, 2024 convertible promissory note disclosed within Note 8, “Convertible Debt,” with the exception that payments on the note may be accelerated or prepaid in full at any time with no prepayment penalty.

On July 23, 2024, we issued a $50,000 promissory note to an unaffiliated third party (the “Holder”). The promissory note, which will incur total interest of $5,000, will mature on February 1, 2025. Monthly payments of $10,000 are due beginning September 1, 2024 and ending January 1, 2025. The $5,000 interest payment is due on February 1, 2025. With the Holder’s permission, the promissory note may be prepaid in full or in part without penalty or premium. In connection with the promissory note, we issued 60,000 common stock warrants with a strike price of $025. The warrants will expire on July 31, 2028.

Subsequent to June 30, 2024, we issued three $25,000 promissory notes to our directors. The promissory notes mature in one year and accrue interest at an annual rate of 9.0%. In connection with the promissory notes, we issued 75,000 common stock warrants to our directors. The warrants, which have a strike price of $0.25, will expire four years after the issuance date.

Issuances of Common Stock

Subsequent to June 30, 2024, we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense.

Second Extension of Standstill Amendment with SMI

Subsequent to June 30, 2024, SMI payments due on July 31, 2024 remained unpaid. On July 31, 2024, the Company and SMI jointly agreed to extend the Standstill Agreement until August 16, 2024, upon which a longer-term agreement is expected to be executed.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act), which provides a “safe harbor” for forward-looking statements made by us. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, results of operations, financial position, business outlook, business trends, and other information, may be forward-looking statements. Words such as “might,” “will,” “may,” “should,” “estimates,” “expects,” “continues,” “contemplates,” “anticipates,” “projects,” “plans,” “potential,” “predicts,” “intends,” “believes,” “forecasts,” “future,” and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates, and projections will occur or can be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those that may be set forth under "Risk Factors" below and elsewhere in this report, as well as in our annual report on Form 10-K for the year ended December 31, 2023 and this quarterly report on Form 10-Q. Examples of these uncertainties and risks include, but are not limited to:

	·	access to sufficient debt or equity capital to meet our operating and financial needs;
	·	the extent of dilution of the holdings of our existing stockholders upon the issuance, conversion or exercise of securities issued as part of our capital raising efforts;
	·	the extent to which certain debt holders may call the notes to be paid;
	·	the effectiveness and ultimate market acceptance of our products and our ability to generate sufficient sales revenues to sustain our growth and strategy plans;
	·	whether our products in development will prove safe, feasible and effective;
	·	whether and when we or any potential strategic partners will obtain required regulatory approvals in the markets in which we plan to operate;
	·	our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;
	·	the lack of immediate alternate sources of supply for some critical components of our products;
	·	our ability to establish and protect the proprietary information on which we base our products, including our patent and intellectual property position;
	·	The impact of the conflict between Russia and Ukraine on economic conditions in general and on our business operations;
	·	the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines;
	·	the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products; and
	·	other risks and uncertainties described from time to time in our reports filed with the SEC.

Table of Contents

These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this filing and are subject to risks and uncertainties. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect thereto or with respect to other forward-looking statements.

The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.

OVERVIEW

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva improves patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our wholly owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants.

Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of June 30, 2024, we have an accumulated deficit of approximately $152.1 million. To date, we have engaged primarily in research and development efforts and the early stages of marketing our products. We do not have significant experience in manufacturing, marketing or selling our products. We may not be successful in growing sales for our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.

Table of Contents

Our product revenues to date have been limited. Our historical and expected future revenue has been and will be derived from sales of LuViva devices and disposables.

Current Demand for LuViva

Based on written agreements and ongoing discussions with our distributors, we currently hold and expect to generate additional purchase orders for approximately $4.2 million in LuViva devices and disposables and expect those purchase orders to result in actual sales of $1.5 to $2.5 million within the next twelve months, representing what we view as current demand for our products. We cannot be assured that we will generate all or any of these additional purchase orders, or that existing orders will not be canceled by the distributors or that parts to build product will be available to meet demand, such that existing orders will result in actual sales. Because we have a short history of sales of our products, we cannot confidently predict future sales of our products beyond this time frame and cannot be assured of any particular number of sales. Accordingly, we have not identified any particular trends with regard to sales of our products. In order to increase demand for LuViva, we are focused on three primary markets: the United States, China and Europe.

In the United States, the Company is actively pursuing FDA approval by initiating a clinical trial protocol involving approximately 400 study participants, with the exact number depending in part on the numbers of women in the study both with and without cervical disease. The protocol was drafted with input from FDA and at least two prestigious clinical centers that are participating in the study. In 2023, FDA completed its review of the protocol and had no further recommendations or questions. Also in 2023, four clinical sites agreed to participate in the study and all four of the study sites are fully IRB approved. All four sites have received LuViva devices and have been trained on their use. One site unexpectedly needed additional approvals from the local hospital that is contributing subjects to the study, but that approval was granted on March 28, 2024. All of the four sites have undergone one or more clinical study monitoring visits by Company clinical study monitors. Clinical study monitoring visits are required by FDA to ensure that the study is being conducted under FDA guidelines and in compliance with the study protocol. Findings from the initial clinical study monitoring visits include:

Approximately 200 patients have been enrolled and tested, which represents approximately half of the patients needed to complete the study.

	2)	There have not been any adverse events reported related to the use of LuViva.

	3)	All three monitored clinical study sites are adhering to the study protocol and are completing the necessary case report forms according to FDA standards.

Based on current and expected enrollment rates, we expect the study to be completed in 2024, however there can be no assurance that the study will progress within the expected timeline.

Regarding international sales efforts, our focus has been on achieving regulatory approval to sell LuViva in China. Our Chinese partner, SMI, has reported to us that as of June 30, 2024, all study subjects needed for Chinese National Medical Products Administration (NMPA) approval have been enrolled and tested. There have been no reports of any adverse events from the study associated with the LuViva device. Filing with the NMPA was temporarily delayed during the second quarter of 2024 due to an unexpected medical leave taken by a clinical medical administrator at one of the clinical sites. SMI believes that they can file the clinical report with NMPA during 2024 and that approval could occur in 2024, although there can be no assurance that NMPA filing and approval will be completed within the projected time frames.

In Europe, our distribution partners, Newmars Medical Technologies (“Newmars”), reported that sales efforts have restarted after delays caused by Covid-19. They are now actively pursuing potential customers in Poland, Hungary and Romania, where we have obtained the required approvals to sell our products though Newmars.

CRITICAL ACCOUNTING POLICIES

Our material accounting policies, which we believe are the most critical to investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. When we begin to generate revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.

Table of Contents

Revenue Recognition: ASC 606, Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps:

Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.

Valuation of Equity Instruments Granted to Employee, Service Providers and Investors: On the date of issuance, the instruments are recorded at their fair value as determined using the Black-Scholes valuation model.

Allowance for Credit Losses: Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of June 30, 2024 and December 31, 2023.

Inventory Valuation: All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased.

RESULTS OF OPERATIONS

COMPARISON OF THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023

Sales Revenue and Cost of Goods Sold: Revenues from the sale of LuViva devices and disposables for the three months ended June 30, 2024, were nil, compared to $44,238 for the three months ended June 30, 2023. Cost of goods sold was nil during the three months ended June 30, 2024, compared to $33,038 during the three months ended June 30, 2023. As of June 30, 2024, we have a deferred revenue balance of $747,780, which will be recognized as revenue when our products are shipped, which is expected to occur late in 2024 upon receiving NMPA approval.

Table of Contents

Research and Development Expenses: Research and development expenses were $221,565 and $66,164 during the three months ended June 30, 2024 and 2023, respectively. The increase of $155,401 or 234.9%, was primarily due to additional $153,764 of costs for sponsored research related to our clinical trials during the three months ended June 30, 2024.

Sales and Marketing Expenses: Sales and marketing expenses were $69,231 and $60,930 during the three months ended June 30, 2024 and 2023, respectively. The increase of $8,300, or 13.6%, was primarily due to $5,008 of additional rent expense allocated to our sales & marketing department and $2,663 of additional travel expenses for sales trips.

General and Administrative Expense: General and administrative expenses were $363,989 and $1,389,034 during the three months ended June 30, 2024 and 2023, respectively. The decrease of $1,025,045, or 73.8%, was primarily driven by a decrease of $697,338 in payroll and benefits (including payroll taxes), which was primarily due to a one-time charge of $679,959 recorded for warrants issued in relation to the appointment of Dr. Mark Faupel as the Company’s President and Chief Executive Officer during the prior year period. Additionally, the Company recognized $59,216 of additional stock-based compensation expense during the prior year period due to the modification of a stock option award and $30,745 of additional expense for stock options for which the related expense was fully recognized as of the end of the prior period. The decrease in general and administrative expenses was also due to a decline of $326,502 of expense for consulting and legal fees, which was primarily driven by $336,745 less expense recognized for shares of common stock and warrants issued to Mr. Blumberg and $29,706 less expense for warrants issued to Mr. Grujic. These decreases were offset by an increase of $39,949 in fees paid to consultants and other third-party professional services providers.

Interest Expense: Interest expense was $75,372 and $68,711 during the three months ended June 30, 2024 and 2023, respectively. The increase of $6,661, or 9.7%, was primarily due to an $8,127 increase in interest due on a local tax liability and $2,019 of additional interest incurred for the promissory note issued to Diagonal Lending during the three months ended June 30, 2024. These increases were offset by decreases in interest expense due to declining balances in other notes payable outstanding.

Change in fair value of derivative liability: The change in the fair value of our derivative liability resulted in a loss of $7,350 during the three months ended June 30, 2024. The change in the fair value was attributed to changes in our forecasted stock price.

Gain from Extinguishment of Debt: The gain from extinguishment of debt of $16,401 and $17,450 during the three months ended June 30, 2024 and 2023, respectively, was materially consistent period over period and was due to forgiveness of debt from our creditors.

Other Income: Other income was $11,515 and $248 during the three months ended June 30, 2024 and 2023, respectively. The change in other income was primarily due to an adjustment of a liability during the three months ended June 30, 2024.

Preferred Stock Dividends: Expense related to preferred stock dividends of $48,929 and $47,497 for the three months ended June 30, 2024 and 2023, respectively, was materially consistent over the two periods.

Net Loss: Net loss attributable to common stockholders was $758,180 and $1,603,219 during the three months ended June 30, 2024 and 2023, respectively. The reasons for the decrease in our net loss are outlined above.

There was no income tax benefit recorded for the three months ended June 30, 2024 or 2023, due to recurring net operating losses.

RESULTS OF OPERATIONS

COMPARISON OF THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Sales Revenue and Cost of Goods Sold: Revenues from the sale of LuViva devices and disposables for the six months ended June 30, 2024, were $5,720, compared to $66,287 for the six months ended June 30, 2023. Cost of goods sold was $1,875 during the six months ended June 30, 2024, compared to $41,827 during the six months ended June 30, 2023. As of June 30, 2024, we have a deferred revenue balance of $747,780, which will be recognized as revenue when our products are shipped, which is expected to occur late in 2024 upon receiving NMPA approval.

Research and Development Expenses: Research and development expenses were $275,119 and $73,310 during the six months ended June 30, 2024 and 2023, respectively. The increase of $201,809 or 275.3%, was primarily due to an increase in costs for clinical trials, including a $186,074 increase in sponsored research costs and $9,593 additional travel expenses for trials during the in the six months ended June 30, 2024.

Table of Contents

Sales and Marketing Expenses: Sales and marketing expenses were $141,803 and $133,975 during the six months ended June 30, 2024 and 2023, respectively. The increase of $7,827, or 5.8% was primarily due to an increase of $7,324 in rent expense allocated to our sales & marketing department.

General and Administrative Expense: General and administrative expenses were $600,216 and $2,165,467 during the six months ended June 30, 2024 and 2023, respectively. The decrease of $1,565,251, or 72.3%, was primarily driven by a decrease of $771,892 in payroll and benefits (including payroll taxes), which was primarily due to a one-time charge of $679,959 recorded for warrants issued in relation to the appointment of Dr. Mark Faupel as the Company’s President and Chief Executive Officer during the prior year period. Additionally, the Company recognized $59,216 of additional stock-based compensation expense during the prior year period due to the modification of a stock option award. The decrease in general and administrative expenses was also due to a decline of $800,040 of expense for consulting and legal fees, which was primarily driven by (1) $696,784 less expense recognized for shares of common stock and warrants issued to Mr. Blumberg, (2) $59,412 less expense for warrants issued to Mr. Grujic and (3) a decline of $43,879 in fees paid to consultants and other third party professional service providers. These decreases were offset by an overall increase of $6,682 in other general and miscellaneous expenses.

Interest Expense: Interest expense was $139,490 and $134,391 during the six months ended June 30, 2024 and 2023, respectively. The increase of $5,099, or 3.8%, was primarily due to a $9,345 increase in interest due on a local tax liability and $2,019 of additional interest incurred for the promissory note issued to Diagonal Lending during the three months ended June 20, 2024. These increases were offset by decreases in interest expense due to declining balances in other notes payable outstanding.

Change in Fair Value of Derivative Liability: The change in the fair value of our derivative liability resulted in a loss of $7,350 during the six months ended June 30, 2024. The change in the fair value was attributed to changes in our forecasted stock price. The gain due to the change in fair value of the derivative liability during the six months ended June 30, 2023 was $5,038 and was attributed to changes in our stock price.

Gain from Extinguishment of Debt: The gain from extinguishment of debt was $33,060 and $52,223 during the six months ended June 30, 2024 and 2023, respectively. The decrease of $19,163, or 36.7% was due to a lower amount of debt forgiven in the current period, as the balances owed to our creditors have declined.

Other Income: Other income was $12,372 and $248 during the six months ended June 30, 2024 and 2023, respectively. The change in other income was primarily due to an adjustment of a liability during the six months ended June 30, 2024.

Deemed Dividend for Warrant Exchanges: Expense for deemed dividends was nil and $65,296 in the six months ended June 30, 2024 and 2023, respectively. The expense in the prior period was recognized as the excess fair value of warrant instruments exchanged over the fair value of the original warrants.

Preferred Stock Dividends: Expense related to preferred stock dividends was $87,836 and $82,255 for the six months ended June 30, 2024 and 2023, respectively. The increase of $5,581, or 6.8%, was due to changes in the value of the common shares used to settle preferred stock dividends in each period.

Net Loss: Net loss attributable to common stockholders was $1,199,452 and $2,572,726 during the six months ended June 30, 2024 and 2023, respectively. The reasons for the decrease in our net loss are outlined above.

There was no income tax benefit recorded for the three months ended June 30, 2024 or 2023, due to recurring net operating losses.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Going Concern Considerations

We have incurred significant losses since our inception. At June 30, 2024, the Company had negative working capital of approximately $4.7 million, accumulated deficit of $152.3 million, and incurred a net loss including preferred dividends of $1.2 million for the six months then ended. Stockholders’ deficit totaled approximately $4.7 million at June 30, 2024, primarily due to recurring net losses from operations.

The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

Liquidity

The Company’s primary liquidity requirements are for working capital, funding clinical studies, and other costs associated with achieving regulatory approval to sell our products. Although income taxes are not currently a significant use of funds, after the benefits of our net operating loss carryforwards are fully recognized, they could become a material use of funds, depending on our future profitability and future tax rates. We anticipate we will require approximately $1.8 million to $2.2 million of funds to operate our business over the next twelve months, including approximately $0.4 million of funds to complete our ongoing clinical studies.

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants. As of June 30, 2024, we had cash of approximately $275 thousand and negative working capital of $4.7 million.

Our major cash flows for the six months ended June 30, 2024 consisted of cash used for operating activities of $314 thousand, proceeds from the issuance of notes payable of $200 thousand and payments of debt and debt issuance costs of $202 thousand.

Table of Contents

Our major cash flows for the six months ended June 30, 2023 consisted of cash used by operating activities of $937 thousand, payments of debt of $213 thousand and proceeds from warrant exercises of $195 thousand.

Off-Balance Sheet Arrangements

We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this item.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain a set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported, within the time periods specified in Securities and Exchange Commission (“Commission”) rules and forms. We carried out an evaluation under the supervision and with the participation of our management, including the Chief Executive Officer/Acting Chief Financial Officer, Mark Faupel, of the effectiveness of its disclosure controls and procedures. Based on that evaluation, the Chief Executive Officer/Acting Chief Financial Officer has concluded that our disclosure controls and procedures were ineffective as of June 30, 2024, due to the existence of material weaknesses in our internal control over financial reporting. The material weaknesses identified arose from a lack of recourses to properly research and account for complex transactions and lack of oversight and approval by the Board of Directors and Audit Committee, including formally documented approval of significant transactions, including related party transactions. While management is currently in the early stages of developing a remediation plan, we have yet to fully remediate this material weakness.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the disposition of these matters, individually or in the aggregate, is not expected to have a material adverse effect on the Company’s financial condition.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K as filed with the SEC on March 28, 2024.

ITEM 2. UNREGISTERRED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the six months ended June 30 2024, the Company issued 400,000 shares of common stock and 900,000 warrants to Richard Blumberg, a related party, pursuant to a consulting agreement. The warrants, which will expire on March 1, 2027, have a strike price of $0.30.

On June 11, 2024, the Company entered into a securities purchase agreement and contingently convertible note with Diagonal Lending. The convertible note issued to Diagonal Lending had a total principal balance of $100,050 and an original issue discount of $13,050. The note, which will accrue total interest of $14,007, will mature on April 15, 2025. A payment of $57,029 is due on the note on December 15, 2024. The remaining balance due, including accrued interest, will be paid in monthly payments of $14,257 from January 15, 2025 through April 15, 2025.

On June 28, 2024, in connection with the issuance of a promissory note, the Company issued the holder 100,000 common stock purchase warrants, which will have an exercise price of $0.25 and will expire on July 1, 2028. The warrants, which had an estimated fair value of $11,998, were recorded as a discount on the note payable.

ITEM 3: DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4: MINE SAFETY DISCLOSURES.

Not applicable

ITEM 5: OTHER INFORMATION.

Issuances of Promissory Notes and Related Warrants

On July 22, 2024, we issued a $62,100 convertible promissory note to Diagonal Lending. The convertible promissory note, which had an original issue discount of $8,100, will mature on May 30, 2025 and will accrue total interest of $8,694. A payment of $35,397 will be due on January 30, 2025. The remaining balance, including the accrued interest, will be paid in monthly installments of $8,849 beginning February 28, 2024 and ending on the maturity date. The remaining terms of the convertible promissory note are identical to the June 11, 2024 convertible promissory note disclosed within Note 8, “Convertible Debt,” with the exception that payments on the note may be accelerated or prepaid in full at any time with no prepayment penalty.

Issuances of Common Stock

Subsequent to June 30, 2024, we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense.

Second Extension of Standstill Amendment with SMI

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number		Exhibit Description

3.1		Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016)
3.2		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012)
3.3		Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018)
3.4		Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020)
3.5		Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021)
3.6		Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021)
3.7		Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021)
3.8		Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022)
3.9		Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022)
10.1*		$100,000 Promissory Note Dated June 28, 2024 and Related Common Stock Purchase Warrant
10.2*		Exchange Agreement dated April 15, 2024
10.3*		Securities Purchase Agreement with 1800 Diagonal Lending
10.4*		$100,050 Promissory Note Dated June 11, 2024 with 1800 Diagonal Lending
10.5*		$50,000 Promissory Note Dated July 23, 2024 and related Common Stock Purchase Warrant Dated August 1, 2024
10.6*		Form of Promissory Notes Issued to Directors and Form of Related Common Stock Purchase Warrants
10.7*		Securities Purchase Agreement with 1800 Diagonal Lending, dated July 22, 2024
10.8*		$62,100 Promissory Note Dated July 22, 2024 with 1800 Diagonal Lending
31*		Rule 13a-14(a)/15d-14(a) Certification
32*		Section 1350 Certification
101.1*		Interactive data files for Guided Therapeutics, Inc. 's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL: (i) the Unaudited Condensed Consolidated Balance Sheets; (ii) the Unaudited Condensed Consolidated Statements of Income; (iii) the Unaudited Condensed Consolidated Statements in Stockholders' Deficit; (iv) the Unaudited Condensed Consolidated Statements of Cash Flows; and (v) the Notes to the Unaudited Condensed Consolidated Financial Statements.
104		The cover page from Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (formatted in Inline XBRL and included in Exhibit 101)

_____________

*Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GUIDED THERAPEUTICS, INC.

	By:	/s/ Mark Faupel
		Mark Faupel
		President, Chief Executive Officer, Chief Operating Officer and Acting Chief Financial Officer

Date: August 14, 2024

nullnullnullnullnullnullnullnullnullnull

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 10, 2024
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		56,550,370
Entity File Number	000-22179
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite B
Entity Address City Or Town	Peachtree Corners
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Local Phone Number	242-8723
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 275	$ 591
Accounts receivable, net of allowance for credit losses of $2 at March 31, 2024 and December 31, 2023	2	7
Inventory, net of reserves of $818 at March 31, 2024 and December 31, 2023	632	632
Other current assets	112	163
Total current assets	1,021	1,393
Non-Current Assets:
Property and equipment, net	28	32
Operating lease right-of-use assets, net of amortization	185	227
Other assets	17	17
Total non-current assets	230	276
TOTAL ASSETS	1,251	1,669
Current Liabilities:
Accounts payable	2,143	1,991
Accounts payable, related parties	34	32
Accrued liabilities	840	1,068
Deferred revenue	748	424
Current portion of lease liability	99	91
Current portion of long-term debt, related parties	520	39
Short-term notes payable	112	59
Short-term convertible debt	94	1,105
Short-term convertible debt in default	1,130	0
Derivative liability at fair value	12	0
Total current liabilities	5,732	4,809
Long-Term Liabilities
Long-term lease liability	104	155
Long-term notes payable	59	0
Long-term debt, related parties	23	511
Total long-term liabilities	186	666
Total liabilities	5,918	5,475
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value; 500,000 shares authorized, 55,614 and 54,105 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	3,442	3,441
Additional paid-in capital	141,320	140,983
Treasury stock at cost	(132)	(132)
Accumulated deficit	(152,317)	(151,118)
Total stockholders' deficit	(4,667)	(3,806)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,251	1,669
Series C Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	105	105
Series C1 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	170	170
Series C2 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	439	439
Series F-2 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	475	475
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	159	159
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	834	834
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	$ 838	$ 838

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable, net of allowance	$ 2,000	$ 2,000
Inventory, net of reserves	$ 818,000	$ 818,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	56,267,000	54,105,000
Common stock, outstanding	54,105,000	54,105,000
Series C Convertible Preferred Shares [Member]
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	9,000.0	9,000.0
Preferred stock, liquidation preference	$ 286,000	$ 286,000
Preferred stock, issued	300	300.0
Preferred stock, outstanding	300.0	300.0
Series F-2 Convertible Preferred Shares [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000.0	5,000.0
Preferred stock, liquidation preference	$ 520,000	$ 520,000
Preferred stock, issued	500	500.0
Preferred stock, outstanding	500.0	500.0
Series D Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	6,000.0	6,000.0
Preferred stock, liquidation preference	$ 438,000	$ 438,000
Preferred stock, issued	400	400.0
Preferred stock, outstanding	400.0	400.0
Series E Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000.0	5,000.0
Preferred stock, liquidation preference	$ 883,000	$ 883,000
Preferred stock, issued	900	900.0
Preferred stock, outstanding	900.0	900.0
Series F Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,500	1,500.0
Preferred stock, liquidation preference	$ 1,006,000	$ 1,006,000
Preferred stock, issued	1,100	1,100.0
Preferred stock, outstanding	1,100.0	1,100.0
Series C-1 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	20,300	20,300.0
Preferred stock, liquidation preference	$ 1,049,000	$ 1,049,000
Preferred stock, issued	1,000.0	1,000.0
Preferred stock, outstanding	1,000.0	1,000.0
Series C-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, liquidation preference	$ 2,700,000	$ 2,700,000
Preferred stock, issued	2,700	2,700.0
Preferred stock, outstanding	2,700.0	2,700.0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Sales - devices and disposables	$ 0	$ 44	$ 6	$ 66
Cost of goods sold	0	33	2	42
Gross profit	0	11	4	24
Operating expenses:
Research and development	222	66	275	73
Sales and marketing	69	61	142	134
General and administrative	364	1,389	600	2,166
Total operating expenses	655	1,516	1,017	2,373
Loss from operations	(655)	(1,505)	(1,013)	(2,349)
Other income (expenses):
Interest expense	(75)	(69)	(139)	(134)
Interest income	0	0	3	0
Change in fair value of derivative liability	(7)	0	(7)	5
Gain from extinguishment of debt	16	17	33	52
Other income (expenses)	12	0	12	0
Total other income (expense)	(54)	(52)	(98)	(77)
Loss before income taxes	(709)	(1,557)	(1,111)	(2,426)
Provision for income taxes	0	0	0	0
Net loss	(709)	(1,557)	(1,111)	(2,426)
Deemed dividend for warrant exchanges	0	0	0	(65)
Preferred stock dividends	(49)	(47)	(88)	(82)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (758)	$ (1,604)	$ (1,199)	$ (2,573)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
Diluted	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
Weighted average shares outstanding
Weighted average shares outstanding Basic	55,986	50,970	55,368	50,138
Weighted average shares outstanding Diluted	55,986	50,970	55,368	50,138

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F2 [Member]	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock
Balance, shares at Dec. 31, 2022		0	1	2	1	1	1	3	48,596
Balance, amount at Dec. 31, 2022	$ (2,883)	$ 105	$ 170	$ 439	$ 159	$ 839	$ 880	$ 489	$ 3,437	$ 138,090	$ (147,359)	$ (132)
Common stock warrants exercised, shares									1,120
Common stock warrants exercised amount	231	0	0	0	0	0	0	0	$ 1	230	0	0
Issuance of common stock for payment of Series D preferred dividends shares									59
Issuance of common stock for payment of Series D preferred dividends amount	14	0	0	0	0	0	0	0	$ 0	14	0	0
Issuance of common stock for payment of Series E preferred dividends shares									26
Issuance of common stock for payment of Series E preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F preferred dividends shares									233
Issuance of common stock for payment of Series F preferred dividends amount	53	0	0	0	0	0	0	0	$ 0	53	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									121
Issuance of common stock for payment of Series F-2 preferred dividends amount	29	0	0	0	0	0	0	0	$ 0	29	0	0
Conversion of Series E preferred stock to common stock shares									20
Conversion of Series E preferred stock to common stock amount	0	0	0	0	0	(5)	0	0	$ 0	5	0	0
Conversion of Series F preferred stock to common stock shares									200
Conversion of Series F preferred stock to common stock amount	0	0	0	0	0	0	(42)	0	$ 0	42	0	0
Conversion of Series F-2 preferred stock to common stock shares									60
Conversion of Series F-2 preferred stock to common stock amount	0	0	0	0	0	0	0	(14)	$ 0	14	0	0
Issuance of common stock for payment of interest shares									178
Issuance of common stock for payment of interest amount	59	0	0	0	0	0	0	0	$ 0	59	0	0
Stock-based compensation shares									400
Stock-based compensation amount	1,683	0	0	0	0	0	0	0	$ 0	1,683	0	0
Impact of warrant exchanges amount	0	0	0	0	0	0	0	0	0	65	(65)	0
Accrued preferred dividends amount	(83)	0	0	0	0	0	0	0	0	(1)	(82)	0
Net Income (Loss)	(2,426)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	0	(2,426)	0
Stock-based compensation	1,683
Balance, shares at Jun. 30, 2023		0	1	2	1	1	1	3	51,011
Balance, amount at Jun. 30, 2023	(3,315)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,438	140,291	(149,932)	(132)
Balance, shares at Mar. 31, 2023		0	1	2	1	1	1	3	50,814
Balance, amount at Mar. 31, 2023	(2,855)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 858	$ 475	$ 3,438	139,127	(148,328)	(132)
Common stock warrants exercised, shares									48
Common stock warrants exercised amount	9	0	0	0	0	0	0	0	$ 0	9	0	0
Issuance of common stock for payment of Series D preferred dividends shares									33
Issuance of common stock for payment of Series D preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									36
Issuance of common stock for payment of Series F-2 preferred dividends amount	9	0	0	0	0	0	0	0	$ 0	9	0	0
Conversion of Series F preferred stock to common stock shares									80
Conversion of Series F preferred stock to common stock amount	0	0	0	0	0	0	(20)	0	$ 0	20	0	0
Net Income (Loss)	(1,557)	0	0	0	0	0	0	0	0	0	(1,557)	0
Stock-based compensation	1,119	0	0	0	0	0	0	0	0	1,119	0	0
Accrued preferred dividends	(48)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	(1)	(47)	0
Balance, shares at Jun. 30, 2023		0	1	2	1	1	1	3	51,011
Balance, amount at Jun. 30, 2023	(3,315)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,438	140,291	(149,932)	(132)
Balance, shares at Dec. 31, 2023		0	1	2	1	1	1	0	54,105
Balance, amount at Dec. 31, 2023	(3,806)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,441	140,983	(151,118)	(132)
Issuance of common stock for payment of Series D preferred dividends shares									125
Issuance of common stock for payment of Series D preferred dividends amount	15	0	0	0	0	0	0	0	$ 0	15	0	0
Issuance of common stock for payment of Series E preferred dividends shares									52
Issuance of common stock for payment of Series E preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F preferred dividends shares									445
Issuance of common stock for payment of Series F preferred dividends amount	54	0	0	0	0	0	0	0	$ 0	54	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									236
Issuance of common stock for payment of Series F-2 preferred dividends amount	27	0	0	0	0	0	0	0	$ 0	27	0	0
Issuance of common stock for payment of interest shares									904
Issuance of common stock for payment of interest amount	105	0	0	0	0	0	0	0	$ 1	104	0	0
Stock-based compensation amount	60	0	0	0	0	0	0	0	0	60	0	0
Accrued preferred dividends amount	(88)	0	0	0	0	0	0	0	0	0	(88)	0
Net Income (Loss)	(1,111)	0	0	0	0	0	0	0	$ 0	0	(1,111)	0
Stock-based compensation	60
Settlement of previously accrued professional fees through common stock issuance shares									400
Settlement of previously accrued professional fees through common stock issuance amount	57	0	0	0	0	0	0	0	$ 0	57	0	0
Issuance of warrants with debt amount	12	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	12	0	0
Balance, shares at Jun. 30, 2024		0	1	2	1	1	1	0	56,267
Balance, amount at Jun. 30, 2024	(4,667)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,442	141,320	(152,317)	(132)
Balance, shares at Mar. 31, 2024			1	2	1	1	1		55,614
Balance, amount at Mar. 31, 2024	(4,012)	105	$ 170	$ 439	$ 159	$ 834	$ 838	475	$ 3,441	141,218	(151,559)	(132)
Issuance of common stock for payment of Series D preferred dividends shares									71
Issuance of common stock for payment of Series D preferred dividends amount	6	0	0	0	0	0	0	0	$ 0	6	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									72
Issuance of common stock for payment of Series F-2 preferred dividends amount	7	0	0	0	0	0	0	0	$ 0	7	0	0
Issuance of common stock for payment of interest shares									510
Issuance of common stock for payment of interest amount	48	0	0	0	0	0	0	0	$ 1	47	0	0
Stock-based compensation amount	30	0	0	0	0	0	0	0	0	30	0	0
Accrued preferred dividends amount	(49)	0	0	0	0	0	0	0	0	0	(49)	0
Net Income (Loss)	(709)	0	0	0	0	0	0	0	0	0	(709)	0
Issuance of warrants with debt amount	12	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	12	0	0
Balance, shares at Jun. 30, 2024		0	1	2	1	1	1	0	56,267
Balance, amount at Jun. 30, 2024	$ (4,667)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,442	$ 141,320	$ (152,317)	$ (132)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,111)	$ (2,426)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	1	2
Depreciation	5	5
Amortization of debt issuance costs and discounts	50	65
Stock-based compensation	60	1,683
Change in fair value of derivative liability	7	(5)
Amortization of lease right-of-use-asset	42	37
Gain from forgiveness of debt	(33)	(52)
Other non-cash expenses	6	11
Change in operating assets and liabilities:
Accounts receivable	4	(3)
Inventory	0	(25)
Other current assets	52	46
Accounts payable and accrued liabilities	323	(173)
Lease liabilities	(44)	(38)
Deferred revenue	324	(64)
NET CASH USED IN OPERATING ACTIVITIES	(314)	(937)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable	200	0
Payments of debt issuance costs	(17)	0
Payments made on notes payable	(185)	(213)
Proceeds from warrant exercises	0	195
NET CASH USED IN FINANCING ACTIVITIES	(2)	(18)
NET CHANGE IN CASH	(316)	(955)
Cash at beginning of period	591	2,313
CASH AT END OF PERIOD	275	1,358
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	21	47
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	88	82
Deemed dividends for warrant exchanges	0	65
Warrants issued with debt	12	0
Beneficial conversion feature	6	0
Common stock issued for payment of interest	105	59
Common stock issued for payment of accrued dividends	104	105
Settlement of previously accrued professional fees through common stock issuance	57	0
Accrued payroll liability exchanged for promissory note	87	0
Conversion of Series E preferred shares into common stock	0	5
Conversion of Series F preferred shares into common stock	$ 0	$ 42

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2024

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION

ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION

1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION

Basis of Presentation

Going Concern

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications did not affect net loss, revenues or stockholders’ equity.

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2024

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES

2. SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Accounting Standard Updates

Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

Concentrations of Credit Risk

Trade Receivables

Inventory Valuation

	(in thousands)
	June 30,			December 31,
	2024			2023

Raw materials	$	1,360		$	1,360
Work-in-progress		46			46
Finished goods		44			44
Inventory reserve		(818	)		(818	)

Total inventory	$	632		$	632

Property and Equipment

	(in thousands)
	June 30,			December 31,
	2024			2023

Equipment	$	951		$	951
Software		634			634
Furniture and fixtures		17			17
Leasehold improvements		12			12

Subtotal		1,614			1,614
Less accumulated depreciation		(1,586	)		(1,582	)
Property, equipment and leasehold improvements, net
	$	28		$	32

Depreciation expense related to property and equipment for the three and six months ended June 30, 2024 and 2023 was not material.

Debt Issuance Costs

Patent Costs (Principally Legal Fees)

Leases

Accrued Liabilities

Accrued liabilities as of June 30, 2024 and December 31, 2023 are summarized as follows:

	(in thousands)
	June 30, 2024		December 31, 2023

Compensation	$	356	$	401
Professional fees		95		216
Interest		143		188
Vacation		29		27
Preferred dividends		210		228
Other accrued expenses		7		8
Total	$	840	$	1,068

Stock Subscription Payable

Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.

Revenue Recognition

	·	Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

	·	Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

	·	Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

	·	Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

	·	Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

Contract Balances

Significant Customers

Research and Development

Income Taxes

Warrants

Stock Based Compensation

Derivatives

Fair Value Measurements

	·	Level 1: Quoted prices for identical assets or liabilities in active markets that the Company can access at the measurement date.

	·	Level 2: Significant other observable inputs other than level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

	·	Level 3: Significant unobservable inputs that reflect the Company’s judgment about the assumptions that market participants would use in pricing an asset or liability.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820:

	·	Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

	·	Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

	·	Income approach: Techniques to convert future amounts to a single present value amount

STOCKHOLDERS DEFICIT

6 Months Ended

Jun. 30, 2024

STOCKHOLDERS' DEFICIT:

STOCKHOLDERS' DEFICIT

3. STOCKHOLDERS’ DEFICIT

Common Stock

During the six months ended June 30, 2024, the Company issued 2,161,560 shares of common stock, as summarized below:

	Number of Shares
Issuance of common stock for payment of Series D preferred dividends		125,505
Issuance of common stock for payment of Series E preferred dividends		52,332
Issuance of common stock for payment of Series F preferred dividends		444,621
Issuance of common stock for payment of Series F-2 preferred dividends		235,544
Issuance of common stock for payment of interest		903,558
Issuance of common stock to consultants		400,000
Total common stock issued during the six months ended June 30, 2024		2,161,560

Summary table of common stock transactions:
Shares outstanding at December 31, 2023		54,105,101
Common shares issued during the six months ended June 30, 2024		2,161,560
Shares outstanding at June 30, 2024		56,266,661

Preferred Stock

Series C Convertible Preferred Stock

Series C1 Convertible Preferred Stock

Series C2 Convertible Preferred Stock

Series D Convertible Preferred Stock

Series E Convertible Preferred Stock

Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, at the option of the Company, shares of common stock.

Series F Convertible Preferred Stock

Series F-2 Convertible Preferred Stock

Warrants

The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the six months ended June 30, 2024 and 2023:

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2023		28,584,580		$	0.50
Warrants issued		1,000,000			0.30
Warrants expired		(761,500	)		0.37
Outstanding, June 30, 2024		28,823,080		$	0.50

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2022		35,586,980		$	0.46
Warrants issued		5,873,750			0.25
Warrants exchanged		(1,025,000	)		0.25
Warrants expired		(9,478,200	)		0.30
Warrants exercised		(973,750	)		0.20
Outstanding, June 30, 2023		29,983,780		$	0.49

Expected term (years)	4.0
Volatility	389.2	%
Risk-free interest rate	4.4	%
Dividend yield	0.0	%

During the six months ended June 30, 2023, management estimated the fair value of the warrants issued utilizing the Black-Scholes Option Pricing model with the following weighted-average assumptions:

Expected term (years)	3.9
Volatility	290.6	%
Risk-free interest rate	3.7	%
Dividend yield	0.0	%

STOCK OPTIONS

6 Months Ended

Jun. 30, 2024

STOCK OPTIONS

STOCK OPTIONS

4. STOCK OPTIONS

The following tables summarize the Company’s stock option activity and related information for the six months ended June 30, 2024 and 2023:

	Number of Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2023		2,338,636	$	0.41	6.5 years	$	-
Options outstanding as of June 30, 2024		2,338,636	$	0.41	6.1 years	$	-
Options exercisable as of June 30, 2024		1,980,114	$	0.43	5.6 years	$	-

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2022		1,500,000		$	0.49	7.5 years	$	-
Options granted		1,025,000		$	0.26
Options forfeited		(186,364	)	$	0.31
Options outstanding as of June 30, 2023		2,338,636		$	0.41	7.1 years	$	-
Options exercisable as of June 30, 2023		1,755,114		$	0.45	6.2 years	$	-

Expected term (years)	10.0
Volatility	366.4	%
Risk-free interest rate	3.8	%
Dividend yield	0.00

Expected term (years)	2.0
Volatility	182.8	%
Risk-free interest rate	4.0	%
Dividend yield	0.0	%

LITIGATION AND CLAIMS

6 Months Ended

Jun. 30, 2024

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS

5. LITIGATION AND CLAIMS

As of June 30, 2024, and December 31, 2023, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2024

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

6. COMMITMENTS AND CONTINGENCIES

Operating Leases

	(in thousands)
	June 30,		December 31
	2024		2023
Operating lease right-of-use assets	$	185	$	227
Operating lease liabilities	$	203	$	246

The table below presents the maturities of operating lease liabilities as of June 30, 2024:

	(in thousands)
	Operating
	Lease Payments
2024 (remaining)		58
2025		118
2026		50
Total future lease payments		226
Less: discount		(23	)
Total lease liabilities	$	203

	(in thousands)
	June 30, 2024			December 31, 2023
Weighted average remaining lease term (years)		1.9			2.4
Weighted average discount rate		11.4	%		11.4	%

Related Party Contracts

Expected term (years)	3.0
Volatility	108.7	%
Risk-free interest rate	4.3	%
Dividend yield	0.0	%

The Company estimated the fair value of the first tranche warrants issued in September 2022 using the Black-Scholes option pricing model with the following assumptions:

Expected term (years)	2.0
Volatility	173.0	%
Risk-free interest rate	3.4	%
Dividend yield	0.0	%

Expense related to the first tranche of warrants was recognized in prior years. Unrecognized expense related to the first tranche warrants was nil as of June 30, 2024.

The Company estimated the fair value of the second tranche warrants using the Binomial Lattice model with the following assumptions:

Expected term (years)	1.0
Volatility	144.4	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

The Company estimated the fair value of the third tranche warrants using the Binomial Lattice model with the following assumptions:

Expected term (years)	2.0
Volatility	172.1	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

Other Commitments

The Company and SMI executed an extension to the Standstill Agreement (the “Second Standstill Extension”) subsequent to June 30, 2024. Please see Note 12, “Subsequent Events” for details.

Contingencies

NOTES PAYABLE

6 Months Ended

Jun. 30, 2024

NOTES PAYABLE

NOTES PAYABLE

7. NOTES PAYABLE

The following table summarizes short-term notes payable (in thousands):

	Short-term notes payable
	June 30, 2024			December 31, 2023
Short-term promissory note	$	100		$	-
Current portion of long-term promissory note		24			-
Premium Finance (insurance)		-			59
Debt Discount		(12	)		-
Short-term notes payable	$	112		$	59

CONVERTIBLE DEBT

6 Months Ended

Jun. 30, 2024

CONVERTIBLE DEBT

CONVERTIBLE DEBT

8. CONVERTIBLE DEBT

10% Senior Unsecured Convertible Debenture

	Senior Secured Convertible Debenture
	June 30, 2024		December 31, 2023
10% Senior Unsecured Convertible Debentures	$	1,130	$	1,130
Unamortized debt issuance costs		-		(12	)
Debt Discount		-		(38	)
Senior Unsecured Convertible Debenture	$	1,130	$	1,080

1800 Diagonal Lending Note

	June 30, 2024			December 31, 2023
Short-term convertible promissory note	$	100		$	-
Unamortized debt issuance costs		(4	)		-
Debt Discount		(12	)		-
Beneficial conversion feature		(5	)		-
1800 Diagonal Lending Convertible Note	$	79		$	-

Auctus Convertible Note

RELATED PARTY DEBT

6 Months Ended

Jun. 30, 2024

RELATED PARTY DEBT

RELATED PARTY DEBT

9. RELATED PARTY DEBT

The tables below summarize the outstanding balance of long-term debt owed to Dr. Faupel and Dr. Cartwright (in thousands):

For Dr. Faupel:

Salary	$	134
Bonus		20
Vacation		95
Interest on compensation		67
Loans to Company		196
Interest on loans		149
Total outstanding prior to exchange		661

Amount forgiven in prior years		(454	)
Amount exchanged for Series F-2 Preferred Stock		(85	)
Total interest accrued through December 31, 2023		57
Balance outstanding at December 31, 2023	$	179

Interest accrued through June 30, 2024		5
Balance outstanding at June 30, 2024	$	184

For Dr.Cartwright

Salary	$	337
Bonus		675
Loans to Company		528
Interest on loans		81
Total outstanding prior to exchange		1,621

Amount forgiven in prior years		(1,302	)
Amount exchanged for Series F-2 Preferred Stock		(100	)
Total interest accrued through December 31, 2023		93
Payments on outstanding debt		(25	)
Balance outstanding at December 31, 2023	$	287

Interest accrued through June 30, 2024		7
Balance outstanding at June 30, 2024	$	294

Future debt obligations at June 30, 2024 for debt owed to related parties is as follows:

Year	Amount (in thousands)
2024 (remaining)		21
2025		519
2026		3
Total	$	543

INCOME (LOSS) PER SHARE OF COMMON STOCK

6 Months Ended

Jun. 30, 2024

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

INCOME (LOSS) PER SHARE OF COMMON STOCK

10. INCOME (LOSS) PER SHARE OF COMMON STOCK

The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data):

	June 30,
	2024			2023

Net loss		(1,199	)		(2,573	)
Basic weighted average number of shares outstanding		55,368			50,138
Net loss per share (basic)		(0.02	)		(0.05	)
Diluted weighted average number of shares outstanding		55,368			50,138
Net loss per share (diluted)		(0.02	)		(0.05	)

FAIR VALUE MEASUREMENTS

6 Months Ended

Jun. 30, 2024

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

11. FAIR VALUE MEASUREMENTS

The key inputs to the valuation model that was utilized to estimate the fair value of the bifurcated conversion option included:

	·	The forecasted future stock prices were determined using historical stock prices and the Company’s equity volatility.
	·	The expected conversion price was determined using the forecast and the contractual term of the convertible note agreement.
	·	The probability of an event of default and timing of a future conversion are based on management’s best estimate of the future settlement of the convertible note.

The following tables present the fair value of the bifurcated conversion option:

	Fair Value at June 30, 2024 (in thousands)
	Level 1		Level 2		Level 3		Total

Derivative liability/bifurcated conversion option in connection with Diagonal Lending $100,050 promissory note		-		-		13		13

Total short-term liabilities at fair value	$	-	$	-	$	13	$	13

Derivative financial instruments and changes thereto recorded in the six months ended June 30, 2024 and 2023 include the following:

	Six Months Ended June 30,
	2024		2023

Balance, beginning of period	$	-	$	(5	)
Inception of derivative liability		5
Change in fair value during the period		7		5

Balance, end of period	$	12	$	-

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2024

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

Issuances of Promissory Notes and Related Warrants

Issuances of Common Stock

Subsequent to June 30, 2024, we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense.

Second Extension of Standstill Amendment with SMI

SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2024

SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Accounting Standard Updates

Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

Concentrations of Credit Risk

Trade Receivables

Inventory Valuation

	(in thousands)
	June 30,			December 31,
	2024			2023

Raw materials	$	1,360		$	1,360
Work-in-progress		46			46
Finished goods		44			44
Inventory reserve		(818	)		(818	)

Total inventory	$	632		$	632

Property and Equipment

	(in thousands)
	June 30,			December 31,
	2024			2023

Equipment	$	951		$	951
Software		634			634
Furniture and fixtures		17			17
Leasehold improvements		12			12

Subtotal		1,614			1,614
Less accumulated depreciation		(1,586	)		(1,582	)
Property, equipment and leasehold improvements, net
	$	28		$	32

Depreciation expense related to property and equipment for the three and six months ended June 30, 2024 and 2023 was not material.

Debt Issuance Costs

Patent Costs (Principally Legal Fees)

Leases

Accrued Liabilities

Accrued liabilities as of June 30, 2024 and December 31, 2023 are summarized as follows:

	(in thousands)
	June 30, 2024		December 31, 2023

Compensation	$	356	$	401
Professional fees		95		216
Interest		143		188
Vacation		29		27
Preferred dividends		210		228
Other accrued expenses		7		8
Total	$	840	$	1,068

Stock Subscription Payable

Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.

Revenue Recognition

	·	Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

	·	Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

	·	Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

	·	Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

	·	Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

Contract Balances

Significant Customers

Research and Development

Income Taxes

Warrants

Stock Based Compensation

Derivatives

Fair Value Measurements

	·	Level 1: Quoted prices for identical assets or liabilities in active markets that the Company can access at the measurement date.

	·	Level 2: Significant other observable inputs other than level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

	·	Level 3: Significant unobservable inputs that reflect the Company’s judgment about the assumptions that market participants would use in pricing an asset or liability.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820:

	·	Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

	·	Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

	·	Income approach: Techniques to convert future amounts to a single present value amount

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2024

SIGNIFICANT ACCOUNTING POLICIES

Schedule of Inventory valuation

	(in thousands)
	June 30,			December 31,
	2024			2023

Raw materials	$	1,360		$	1,360
Work-in-progress		46			46
Finished goods		44			44
Inventory reserve		(818	)		(818	)

Total inventory	$	632		$	632

Schedule of Property and equipment

	(in thousands)
	June 30,			December 31,
	2024			2023

Equipment	$	951		$	951
Software		634			634
Furniture and fixtures		17			17
Leasehold improvements		12			12

Subtotal		1,614			1,614
Less accumulated depreciation		(1,586	)		(1,582	)
Property, equipment and leasehold improvements, net
	$	28		$	32

Schedule of Accrued liabilities

	(in thousands)
	June 30, 2024		December 31, 2023

Compensation	$	356	$	401
Professional fees		95		216
Interest		143		188
Vacation		29		27
Preferred dividends		210		228
Other accrued expenses		7		8
Total	$	840	$	1,068

STOCKHOLDERS DEFICIT (Tables)

6 Months Ended

Jun. 30, 2024

STOCKHOLDERS' DEFICIT:

Schedule of Common stock issued

	Number of Shares
Issuance of common stock for payment of Series D preferred dividends		125,505
Issuance of common stock for payment of Series E preferred dividends		52,332
Issuance of common stock for payment of Series F preferred dividends		444,621
Issuance of common stock for payment of Series F-2 preferred dividends		235,544
Issuance of common stock for payment of interest		903,558
Issuance of common stock to consultants		400,000
Total common stock issued during the six months ended June 30, 2024		2,161,560

Summary table of common stock transactions:
Shares outstanding at December 31, 2023		54,105,101
Common shares issued during the six months ended June 30, 2024		2,161,560
Shares outstanding at June 30, 2024		56,266,661

Schedule of Company's outstanding warrants to purchase common stock

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2023		28,584,580		$	0.50
Warrants issued		1,000,000			0.30
Warrants expired		(761,500	)		0.37
Outstanding, June 30, 2024		28,823,080		$	0.50

	Warrants (Underlying Shares)			Weighted-Average Exercise Price Per Share

Outstanding, December 31, 2022		35,586,980		$	0.46
Warrants issued		5,873,750			0.25
Warrants exchanged		(1,025,000	)		0.25
Warrants expired		(9,478,200	)		0.30
Warrants exercised		(973,750	)		0.20
Outstanding, June 30, 2023		29,983,780		$	0.49

Schedule of fair value warrants issued under Black-Scholes Option Pricing model

Expected term (years)	4.0
Volatility	389.2	%
Risk-free interest rate	4.4	%
Dividend yield	0.0	%

Expected term (years)	3.9
Volatility	290.6	%
Risk-free interest rate	3.7	%
Dividend yield	0.0	%

STOCK OPTIONS (Tables)

6 Months Ended

Jun. 30, 2024

STOCK OPTIONS

Schedule of Stock options vested, unvested and granted

	Number of Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2023		2,338,636	$	0.41	6.5 years	$	-
Options outstanding as of June 30, 2024		2,338,636	$	0.41	6.1 years	$	-
Options exercisable as of June 30, 2024		1,980,114	$	0.43	5.6 years	$	-

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value of In-the-Money Options (in thousands)

Options outstanding as of December 31, 2022		1,500,000		$	0.49	7.5 years	$	-
Options granted		1,025,000		$	0.26
Options forfeited		(186,364	)	$	0.31
Options outstanding as of June 30, 2023		2,338,636		$	0.41	7.1 years	$	-
Options exercisable as of June 30, 2023		1,755,114		$	0.45	6.2 years	$	-

Schedule of Stock option activity

Expected term (years)	10.0
Volatility	366.4	%
Risk-free interest rate	3.8	%
Dividend yield	0.00

Expected term (years)	2.0
Volatility	182.8	%
Risk-free interest rate	4.0	%
Dividend yield	0.0	%

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2024

Fair value of the warrants using the Black-Scholes option pricing model

Expected term (years)	3.0
Volatility	108.7	%
Risk-free interest rate	4.3	%
Dividend yield	0.0	%

Schedule of Operating lease right-of-use assets and lease liabilities

	(in thousands)
	June 30,		December 31
	2024		2023
Operating lease right-of-use assets	$	185	$	227
Operating lease liabilities	$	203	$	246

Schedule of Maturities of operating lease liabilities

	(in thousands)
	Operating
	Lease Payments
2024 (remaining)		58
2025		118
2026		50
Total future lease payments		226
Less: discount		(23	)
Total lease liabilities	$	203

Schedule of Weighted-average remaining lease term and discount rate

	(in thousands)
	June 30, 2024			December 31, 2023
Weighted average remaining lease term (years)		1.9			2.4
Weighted average discount rate		11.4	%		11.4	%

Tranche Three [Member]

Fair value of the warrants using the Black-Scholes option pricing model

Expected term (years)	2.0
Volatility	172.1	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

Tranche Two [Member]

Fair value of the warrants using the Black-Scholes option pricing model

Expected term (years)	1.0
Volatility	144.4	%
Risk-free interest rate	3.6	%
Dividend yield	0.0	%

Tranche One [Member]

Fair value of the warrants using the Black-Scholes option pricing model

Expected term (years)	2.0
Volatility	173.0	%
Risk-free interest rate	3.4	%
Dividend yield	0.0	%

NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2024

NOTES PAYABLE

Schedule of Short-term notes payable, including related parties

	Short-term notes payable
	June 30, 2024			December 31, 2023
Short-term promissory note	$	100		$	-
Current portion of long-term promissory note		24			-
Premium Finance (insurance)		-			59
Debt Discount		(12	)		-
Short-term notes payable	$	112		$	59

CONVERTIBLE DEBT (Tables)

6 Months Ended

Jun. 30, 2024

CONVERTIBLE DEBT

Scheduled of unamortized debt issuance costs

	Senior Secured Convertible Debenture
	June 30, 2024		December 31, 2023
10% Senior Unsecured Convertible Debentures	$	1,130	$	1,130
Unamortized debt issuance costs		-		(12	)
Debt Discount		-		(38	)
Senior Unsecured Convertible Debenture	$	1,130	$	1,080

Scheduled of note payable discount, unamortized debt issuance costs and unamortized debt discount

	June 30, 2024			December 31, 2023
Short-term convertible promissory note	$	100		$	-
Unamortized debt issuance costs		(4	)		-
Debt Discount		(12	)		-
Beneficial conversion feature		(5	)		-
1800 Diagonal Lending Convertible Note	$	79		$	-

RELATED PARTY DEBT (Tables)

6 Months Ended

Jun. 30, 2024

RELATED PARTY DEBT

Schedule of Long-term debt, related parties

For Dr. Faupel:

Salary	$	134
Bonus		20
Vacation		95
Interest on compensation		67
Loans to Company		196
Interest on loans		149
Total outstanding prior to exchange		661

Amount forgiven in prior years		(454	)
Amount exchanged for Series F-2 Preferred Stock		(85	)
Total interest accrued through December 31, 2023		57
Balance outstanding at December 31, 2023	$	179

Interest accrued through June 30, 2024		5
Balance outstanding at June 30, 2024	$	184

For Dr.Cartwright

Salary	$	337
Bonus		675
Loans to Company		528
Interest on loans		81
Total outstanding prior to exchange		1,621

Amount forgiven in prior years		(1,302	)
Amount exchanged for Series F-2 Preferred Stock		(100	)
Total interest accrued through December 31, 2023		93
Payments on outstanding debt		(25	)
Balance outstanding at December 31, 2023	$	287

Interest accrued through June 30, 2024		7
Balance outstanding at June 30, 2024	$	294

Schedule of Long-term debt, related parties debt obligations

Year	Amount (in thousands)
2024 (remaining)		21
2025		519
2026		3
Total	$	543

INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables)

6 Months Ended

Jun. 30, 2024

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

Schedule of Earnings per share

	June 30,
	2024			2023

Net loss		(1,199	)		(2,573	)
Basic weighted average number of shares outstanding		55,368			50,138
Net loss per share (basic)		(0.02	)		(0.05	)
Diluted weighted average number of shares outstanding		55,368			50,138
Net loss per share (diluted)		(0.02	)		(0.05	)

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2024

FAIR VALUE MEASUREMENTS

Schedule of fair value for liabilities measured on a recurring basis

	Fair Value at June 30, 2024 (in thousands)
	Level 1		Level 2		Level 3		Total

Derivative liability/bifurcated conversion option in connection with Diagonal Lending $100,050 promissory note		-		-		13		13

Total short-term liabilities at fair value	$	-	$	-	$	13	$	13

Schedule of change in fair value instruments

	Six Months Ended June 30,
	2024		2023

Balance, beginning of period	$	-	$	(5	)
Inception of derivative liability		5
Change in fair value during the period		7		5

Balance, end of period	$	12	$	-

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION
Accumulated deficit	$ (152.3)
Total stockholders' deficits	(4.7)
Working capital	(4.7)
Net loss including preferred dividend	(1.2)
Proceeds from warrant exercises	$ 0.2	$ 0.4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,360	$ 1,360
Work in process	46	46
Finished goods	44	44
Inventory reserve	(818)	(818)
Total	$ 632	$ 632

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 1,614	$ 1,614
Less accumulated depreciation	(1,586)	(1,582)
Property, equipment and leasehold improvements, net	28	32
Equipment [Member]
Property and equipment, gross	951	951
Furniture and Fixtures [Member]
Property and equipment, gross	17	17
Software [Member]
Property and equipment, gross	634	634
Leasehold Improvement [Member]
Property and equipment, gross	$ 12	$ 12

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 356	$ 401
Professional fees	95	216
Interest	143	188
Vacation	29	27
Preferred dividends	210	228
Other accrued expenses	7	8
Total	$ 840	$ 1,068

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Accounts receivable	$ 2,047		$ 7,442
Accounts receivable, net of allowance	450		1,500
Deferred revenue	747,780		424,225	$ 509,101
Remaining net operating loss	3,800,000
Net operating loss carry forward	$ 66,400,000
Percentage amount of tax benefit	50.00%
Excess of insured limitations	$ 156,112		$ 156,112
Consultants and Executives [Member]
Expense for warrants		$ 1,361,143
Director [Member]
Expense related to stock options	29,673	206,306
Expense for warrants	$ 30,932	$ 116,000

STOCKHOLDERS DEFICIT (Details)	6 Months Ended
STOCKHOLDERS DEFICIT (Details)	Jun. 30, 2024 shares
Issuances of common stock	2,161,560
Share outstanding, beginning	54,105,101
Common shares issued during the year ended	2,161,560
Share outstanding, ending	56,266,661
Issuances of Common Stock for Payment of Series D Preferred Dividends [Member]
Issuances of common stock	125,505
Issuances of Common Stock for Payment of Series E Preferred Dividends [Member]
Issuances of common stock	52,332
Issuances of Common Stock for Payment of Series F Preferred Dividends [Member]
Issuances of common stock	444,621
Issuances of Common Stock for Payment of Series F-2 Preferred Dividends [Member]
Issuances of common stock	235,544
Issuances of Common Stock for Payment of Interest [Member]
Issuances of common stock	903,558
Issuance of Common Stock to Consultants [Member]
Issuances of common stock	400,000

STOCKHOLDERS DEFICIT (Details 1) - USD ($)	6 Months Ended
STOCKHOLDERS DEFICIT (Details 1) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS' DEFICIT:
Warrants outstanding, beginning balance	28,584,580	35,586,980
Warrants issued	1,000,000	5,873,750
Warrants cancelled/expired	(761,500)	(9,478,200)
Warrants exchanged		$ (1,025,000)
Warrants exercised		(973,750)
Warrants outstanding, ending balance	28,823,080	29,983,780
Weighted Average Exercise Price Per Share, beginning balance	$ 0.50	$ 0.46
Weighted Average Exercise Price Per Share, Warrants issued	0.30	0.25
Weighted Average Exercise Price Per Share, Warrants cancelled/expired	0.37	0.25
Weighted Average Exercise Price Per Share, Warrants exchanged		0.30
Weighted Average Exercise Price Per Share, Warrants exercised		0.20
Weighted Average Exercise Price Per Share, ending balance	$ 0.50	$ 0.49

STOCKHOLDERS DEFICIT (Details 2)	6 Months Ended
STOCKHOLDERS DEFICIT (Details 2)	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS' DEFICIT:
Expected term	4 years	3 years 10 months 24 days
Volatility	389.20%	290.60%
Risk-free interest rate	4.40%	3.70%
Dividend yield	0.00%	0.00%

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)		6 Months Ended		12 Months Ended
STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	May 14, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2021
Stock-based compensation expense		$ 29,673	$ 206,306
Common stock, par value		$ 0.001		$ 0.001
Outstanding shares exchanged to Preferred stock		53,674,649	54,482,496
Chinese National Medical Products Administration [Member]
Issuance of common stock	4,000,000
Strike price of warrants	$ 0.40
Warrant vested shares	1,500,000
Exercisable term	10 years
Food And Drug Administration [Member]
Warrant vested shares	2,500,000
Warrant [Member] \| Mark Faupel [Member]
Issuance of common stock	4,000,000
Stock-based compensation expense			$ 679,959
Strike price of warrants	$ 0.25
Warrants Exchanges - 2021 [Member]
Common stock warrants		973,750
Strike price of warrants		$ 0.25	$ 0.25
Unpaid accrued dividends			$ 65,296
Exchange common stock warrants			1,025,000
Common stock warrants strike price per share			$ 0.20
Exercise of warrants, value			$ 194,750
Exercise of warrants, shares			973,750
Warrants Exchanges - 2021 [Member] \| Richard Blumberg [Member]
Number of warrant issued		900,000	900,000
Series C Convertible Preferred Shares [Member]
Note payable to an unaffiliated third party		$ 100,000
Issuance of common stock		100,000
Common stock, shares authorized		500,000,000		500,000,000
Common stock shares issued		56,266,661		54,105,101
Common stock shares outstanding		56,266,661		54,105,101
Conversion price per share		$ 0.50
Common stock, par value		$ 0.001		$ 0.001
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		572,000
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares designated		9,000		9,000
Liquidation preference		$ 1,000		$ 1,000
Make-whole payment shares		200		200
Unpaid accrued dividends		$ 120,120		$ 120,120
Preferred stock shares issued		300		300.0
Preferred stock shares outstanding		300.0		300.0
Cumulative dividend rate		12.00%
Preferred stock shares authorized		9,000.0		9,000.0
Series C1 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.50
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		2,098,500
Preferred stock shares designated		20,250
Preferred stock shares issued		1,049		1,049
Preferred stock shares outstanding		1,049		1,049
Series C2 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.50
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		5,400,000
Preferred stock shares surrendered		3,262
Dividing the stated value		1,000
Preferred stock shares issued		3,262
Preferred stock shares outstanding		2,700		2,700
Series F-2 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock shares converts into common stock		4,000
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares designated		3,500
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share		$ 1,000
Outstanding shares exchanged to Preferred stock		2,559
Preferred stock shares issued		500		500.0
Percentage of dividend		6.00%
Increased beneficial ownership percentage		9.99%
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200.00%
Preferred stock shares outstanding		520		520
Preferred stock shares received		678,000
Accrued dividends of preferred shares		$ 7,918		$ 23,579
Outstanding debt		$ 2,559,000
Issuance of common stock for conversion of Series F-2 Convertible Preferred Stock		235,544
Preferred stock shares outstanding		500.0		500.0
Preferred stock shares authorized		5,000.0		5,000.0
Series D Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock, par value		$ 0.001
Preferred stock shares designated		6,000
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share		$ 750
Preferred stock shares issued		763
Increased beneficial ownership percentage		9.99%
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200.00%
Preferred stock converted share		3,000
Shares issued common stock amount		$ 763,000
Common stock, issued public shares		1,526,000
Shares issued for payment of accured stock dividend		$ 125,505
Warrant exercise price per share		$ 0.25
Common stock warrants exercise price 1		$ 0.75
Preferred stock dividends accrued		$ 8,360		$ 8,360
Series E Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock, par value		$ 0.001
Preferred stock shares designated		5,000
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Liquidation preference		$ 883		883
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200.00%
Issuance of common stock for conversion of Series E Convertible Preferred Stock		52,332
Increased election holder		9.99%
Preferred stock stated value		$ 1,000
Accrued dividends		$ 57,592		$ 30,272
Cumulative dividends, per annum		8.00%
Series F Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock shares converts into common stock					4,000
Preferred stock shares designated		1,500
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share					$ 1,000
Preferred stock shares issued		1,006		1,006
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200.00%
Shares issued common stock amount					$ 1,436,000
Issuance of common stock for conversion of Series F Convertible Preferred Stock		444,621
Increased election holder		9.99%
Preferred stock shares outstanding					1,436
Cumulative dividend rate					6.00%
Accrued dividends		$ 15,761		$ 46,108
Preferred Stock Shares [Member]
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares authorized		5,000,000		500,000,000

STOCK OPTIONS (Details) - USD ($)	6 Months Ended
STOCK OPTIONS (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
STOCK OPTIONS
Outstanding at beginning of year	2,338,636	1,500,000
Options granted		1,025,000
Options forfeited		(186,364)
Outstanding at ending of year	2,338,636	2,338,636
Number of shares exercisable	1,980,114	1,755,114
Options outstanding weighted average exercise price, beginning	$ 0.41	$ 0.49
Options granted weighted average exercise price	0.26	0.26
Options forfeited weighted average exercise price		0.31
Options outstanding weighted average exercise price, Ending	0.41	0.41
Weighted average exercise price per share exercisable	$ 0.43	$ 0.45
Weighted average remaining contractual life, Beginning	6 years 6 months	7 years 6 months
Weighted average remaining contractual life, Ending	6 years 1 month 6 days	7 years 1 month 6 days
Weighted average remaining contractual life exercisable	5 years 7 months 6 days	6 years 2 months 12 days
Agrregate intrensic value, Beginning	$ 0	$ 0
Agrregate intrensic value, Ending	0	0
Agrregate intrensic value exercisable	$ 0	$ 0

STOCK OPTIONS (Details 1)		6 Months Ended
STOCK OPTIONS (Details 1)	Mar. 03, 2023	Jun. 30, 2023
Dr. Cartwright [Member]
Expected term (years)	2 years
Volatility	182.80%
Risk-free interest rate	4.00%
Dividend yield	0.00%
Black-Scholes Option [Member]
Expected term (years)		10 years
Volatility		366.40%
Risk-free interest rate		3.80%
Dividend yield		0.00%

STOCK OPTION (Details Narrative) - USD ($)				6 Months Ended
STOCK OPTION (Details Narrative) - USD ($)	Mar. 07, 2023	Mar. 03, 2023	Feb. 10, 2023	Jun. 30, 2024	Jun. 30, 2023
Unrecognized stock-based compensation expense				$ 94,578
Weighted average period				1 year 9 months
Aggregate number of common shares				2,500,000
Options granted weighted average exercise price				$ 0.26	$ 0.26
Vesting period, description	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023		One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023
Stock-based compensation expense				$ 29,673	$ 206,306
Director [Member]
Stock option expense				$ 29,673	206,306
Exercise price			$ 0.2629
Options granted			925,000
Maturity date			Feb. 09, 2033
Dr. Cartwright [Member]
Unvested stock options forfeited		186,364
Stock option expense					$ 59,216
Alan Gurjic [Member]
Exercise price	$ 0.27
Options granted	100,000
Maturity date	Mar. 06, 2033

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
Operating lease right-of-use assets	$ 185	$ 227
Operating lease liabilities	$ 203	$ 246

COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
2024 (remaining)	$ 58
2025	118
2026	50
Total future lease payments	226
Less: discount	(23)
Total lease liabilities	$ 203	$ 246

COMMITMENTS AND CONTINGENCIES (Details 2)	6 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details 2)	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
Weighted average remaining lease term (years)	1 year 10 months 24 days	2 years 4 months 24 days
Weighted average discount rate	11.40%	11.40%

COMMITMENTS AND CONTINGENCIES (Details 3)	6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details 3)	Jun. 30, 2024	Jun. 30, 2023
Expected term (years)	4 years	3 years 10 months 24 days
Volatility	389.20%	290.60%
Risk-free interest rate	4.40%	3.70%
Dividend yield	0.00%	0.00%
Tranche Three [Member]
Expected term (years)	2 years
Volatility	3.60%
Risk-free interest rate	172.10%
Dividend yield	0.00%
Tranche Two [Member]
Expected term (years)	1 year
Volatility	3.60%
Risk-free interest rate	144.40%
Dividend yield	0.00%
Tranche One [Member]
Expected term (years)	2 years
Volatility	3.40%
Risk-free interest rate	173.00%
Dividend yield	0.00%
Richard Blumberg [Member]
Expected term (years)	3 years
Volatility	108.70%
Risk-free interest rate	4.30%
Dividend yield	0.00%

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended						3 Months Ended		6 Months Ended
	Mar. 10, 2021	Sep. 06, 2016	Jun. 05, 2016	Jul. 31, 2024	May 31, 2024	Apr. 26, 2024	Mar. 27, 2024	Feb. 17, 2024	Aug. 24, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 28, 2024	Jan. 22, 2020
Royalty percent			20.00%
Operating lease cost												$ 27,351	$ 54,702
Payment to advisory group per months												2,000
Description of standstill agreement						contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545
Warrants broken into four tranches															1,250,000
Strike price															$ 0.25
Warrants exercise prices														$ 0.25
Commitments Other [Member]
Consideration amount company received												$ 885,144
Tranche Second and Third [Member]
Stock price										$ 1.50		$ 1.50
Tranche Second [Member]
Recognized expense										$ 29,706	$ 29,706	$ 0	59,412
Unrecognized expense												0
Tranche Third [Member]
Recognized expense										$ 15,466	$ 15,466	30,932	30,932
Unrecognized expense												10,311
Shenghuo Medical, LLC [Member]
Payment receive descriptions			Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million
Royalty Agreement [Member]
Royalty consideration		$ 50,000
Agreement Smi Fund [Member]
Amendment payment from SMI								$ 531,100
Description related to SMI fund agreement								SMI, through SMI’s authorized distribution partner, initiated a wire payment of $330,000 in partial satisfaction of $531,100 owed to the Company
Description related to standstill agreement							The parties agreed that SMI will make a nonrefundable payment of $100,000 to the Company prior to March 31, 2024. In exchange, the Company will not initiate any legal proceedings, including but not limited to filing a lawsuit, obtaining a judgement, or enforcing any security interest, as related to the March shortfall in payments of $201,100, until April 30, 2024. Upon paying $100,000, SMI will have the option to extend the Standstill Agreement until June 15, 2024 by making a nonrefundable payment to the Company of $150,000
Additional Commitment payment				$ 500,000	$ 200,000
Additional payments												4,000,000.0
Consideration for inventory payment												$ 4,400,000
Alan Gurjic [Member]
Excercise price									$ 0.75
Weighted average price									$ 1.50
Advisory Group \| Consulting Agreement [Member]
Warrants										831,250		831,250			5,000,000
Number of warrants issued										2,500,000		2,500,000
Strike price										$ 0.20		$ 0.20
Ironstone capital corp and Alan Gurjic [Member] \| Consulting Agreement [Member]
Issued warrants									800,000
Excercise price									$ 0.50
Weighted average price									$ 1.00
Mr. Blumberg [Member]
Issued warrants									600,000			900,000
Shares issued	400,000
Mr. Blumberg [Member] \| Consulting Agreement [Member]
Terms of amendment to agreement	3,600,000 3-year warrants with exercise prices ranging from $0.30 - $0.60, and (2) 1,600,000 common stock shares. On September 30, 2021, the Company and Mr. Blumberg entered into an amended agreement, pursuant to which issuance of the warrants and common shares became predicated on the Company obtaining financing or a series of financings resulting in minimum receipts of at least $1.0 million	royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20
Recognized expenses for Warrants issued												$ 0	590,840
Recognized expenses for common stock												$ 7,425	$ 111,833
Number of outstanding warrants for exchange													875,000
Subscription receivable	$ 350,000
Warrants exercise prices	$ 0.30
Mr. Blumberg [Member]
Number of warrants issued										1,750,000		1,750,000
Non-related parties [Member]
Number of warrants issued										750,000		750,000
Third Party [Member]
Issued warrants									600,000

NOTES PAYABLE (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Short-term notes payable	$ 112	$ 59
Debt Discount	(12)	0
Premium Finance (Insurance) [Member]
Short-term notes payable	0	59
Short-Term Promissory Note [Member]
Short-term notes payable	100	0
Current Portion of Long-Term Promissory Note [Member]
Short-term notes payable	$ 24	$ 0

NOTES PAYABLE (Details Narrativeg) - USD ($)		1 Months Ended
NOTES PAYABLE (Details Narrativeg) - USD ($)	Jul. 04, 2023	Jun. 28, 2024	Apr. 15, 2024	Jun. 30, 2024	Dec. 31, 2023
Monthly payment	$ 12,041	$ 20,000	$ 2,000
Deferred compensation			81,768
Outstanding principal balance				$ 0	$ 59,422
Promissory note		$ 100,000	$ 87,162	83,162
Common stock purchase warrants		100,000
Short term note payable				112,000	59,000
Long term note payable				59,000	$ 0
Accrued interest		$ 10,000
Exercise price		$ 0.25
Discount on note payable		$ 11,998
Line of credit facility, maximum borrowing capacity	$ 129,073
Promissory note maturity date	May 04, 2024	Jan. 01, 2025	May 05, 2028
Accrued interest rate	7.90%		6.00%
Note payable [Member]
Short term note payable				24,000
Long term note payable				$ 59,162

CONVERTIBLE DEBT (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
1800 Diagonal Lending Convertible Note [Member]
Debt Discount	$ (12)	$ 0
Long-term convertible debt	79	0
Short-term convertible promissory note	100	0
Unamortized debt issuance costs	(4)	0
Beneficial conversion feature	(5)	0
10% Senior Unsecured Convertible Debenture [Member]
10% Senior Unsecured Convertible Debentures	1,130	1,130
Debt Issuance costs to be amortized	0	(12)
Debt Discount	0	(38)
Long-term convertible debt	$ 1,130	$ 1,080

CONVERTIBLE DEBT (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended
CONVERTIBLE DEBT (Details Narrative) - USD ($)	Jun. 11, 2024	Sep. 02, 2022	May 17, 2021	Jun. 30, 2024	Jun. 28, 2024	Apr. 15, 2024	Dec. 31, 2023	Sep. 01, 2022	Dec. 17, 2019
Convertible promissory note									$ 2,400,000
Convertible debt conversion price description				The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date)
Trading price									$ 0.04
Variable conversion price									$ 0.15
Early prepayment penalty		$ 350,000
Default premiums		281,256
Interest payable		91,555
Reduced amount owed to Auctus after the Exchange		$ 710,911
Warrants exchanged by Auctus		8,775,000
Default penalty forgiven by Auctus		$ 225,444
Interest rate				24.00%
Notes payable				$ 83,162	$ 100,000	$ 87,162
Auctus [Member]
Accrued interest				115,646			$ 121,995
Share Issue		3,900,000
Prepayment penalty								$ 350,000
Total balance of the convertible debt outstanding				15,000			25,000	$ 1,228,183
Warrant One [Member]
Warrant exchange price		$ 0.50
Warrant to purchase								3,900,000
Warrant Two [Member]
Warrant exchange price		0.65
Warrant to purchase								3,900,000
Minimum [Member]
Warrant exchange price		0.15
Maximum [Member]
Warrant exchange price		$ 0.20
10% Senior Unsecured Convertible Debenture [Member]
Convertible promissory note			$ 1,000	1,130,000
Accrued interest				$ 24,860			$ 58,494
Convertible debentures right description			each debenture unit included 1,000 common stock warrants with an exercise price of $0.80 and an expiration date of May 17, 2023
Change of Control premium percentage			3.00%
Default interest rate				18.00%
Senior Secured Convertible rate			10.00%
Deemed price			$ 0.50
Debt maturity date			May 17, 2024	May 17, 2024
Proceeds from convertible debenture			$ 1,130,000
Conversion price			$ 0.50
1800 Diagonal Lending Note [Member]
Convertible promissory note				$ 100,000
Accrued interest	$ 14,007			$ 1,166
Convertible note principal balance	100,050
Discount on convertible note	13,050
Notes payable	$ 57,029
Debt maturity date	Apr. 15, 2025
Convertible note monthly payments	$ 14,257

RELATED PARTY DEBT (Details) - USD ($) $ in Thousands	6 Months Ended
RELATED PARTY DEBT (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Bonus	$ 356	$ 401
Vacation	29	27
Dr. Cartwright [Member]
Salary	337
Bonus	675
Loans to Company	528
Interest on loans	81
Total outstanding prior to exchange	1,621
Amount forgiven in prior years	(1,302)
Total interest accrued	7	93
Balance outstanding, end of period	294	287
Amount exchanged for Series F-2 Preferred Stock	(100)
Payments on outstanding debt		(25)
Dr. Faupel [Member]
Salary	134
Bonus	20
Vacation	95
Interest on compensation	67
Loans to Company	196
Interest on loans	149
Total outstanding prior to exchange	661
Amount forgiven in prior years	(454)
Amount exchanged for Series F-2 Preferred Stock	(85)
Total interest accrued	5	57
Balance outstanding, end of period	$ 184	$ 179

RELATED PARTY DEBT (Details 1) - Long-Term Debt - Related Parties [Member] - Mr. Fowler [Member] $ in Thousands	Jun. 30, 2024 USD ($)
2024 (remaining)	$ 21
2025	519
2026	3
Total	$ 543

RELATED PARTY DEBT (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
RELATED PARTY DEBT (Details Narrative) - USD ($)	Mar. 22, 2021	Feb. 19, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jul. 14, 2018
Deferred compensation				$ 1,119,000	$ 60,000	$ 1,683,000
Dr. Cartwright [Member]
Promissory note interest rate		6.00%
Debt instrument converted amount		$ 100,000
Series F-2 Preferred Stock issued upon conversion of debt		100
Principal amount of promissory note		$ 267,085
Issuance of promissory note in exchange of related party debt								$ 319,000
Loans, interest, bonus, salary and vacation paid amount								$ 1,621,499
Interest rate per annum								6.00%
Dr. Faupel [Member]
Due to related party								$ 660,895
Promissory note interest rate		6.00%
Debt instrument converted amount		$ 85,000
Series F-2 Preferred Stock issued upon conversion of debt		85
Principal amount of promissory note		$ 153,178
Issuance of promissory note in exchange of related party debt								$ 207,111
Mr. Fowler [Member]
Deferred compensation			$ 16,401	$ 17,450	33,060	$ 35,171
Total outstanding prior to exchange			96,276		96,276
Long-term debt-related parties			$ 63,731		$ 63,731		$ 82,945
Due to related party	$ 546,214
Series F-2 Preferred Stock issued upon conversion of debt	50
Interest payable	$ 133,590
Due to related party, amount	$ 546,214
Promissory note default interest rate	18.00%
Promissory note monthly installment	$ 3,600
Preferred shares converted into common stock	200,000
Effective interest rate	6.18%
Deferred salary	$ 412,624
Unsecured note issued upon conversion of debt	$ 150,000

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Net loss	$ (758)	$ (1,604)	$ (1,199)	$ (2,573)
Basic weighted average number of shares outstanding			55,368	50,138
Net loss per share (basic)			$ (0.02)	$ (0.05)
Diluted weighted average number of shares outstanding			55,368	50,138
Net loss per share (diluted)			$ (0.02)	$ (0.05)

INCOME (LOSS) PER COMMON SHARE (Details Narrative) - shares	Jun. 30, 2024	Jun. 30, 2023
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Convertible common shares	53,674,649	54,482,496

FAIR VALUE MEASUREMENTS (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Derivative liability	$ 13
Total short-term liabilities at fair value	13
Level 1 [Member]
Derivative liability	0
Total short-term liabilities at fair value	0
Level 2 [Member]
Derivative liability	0
Total short-term liabilities at fair value	0
Level 3 [Member]
Derivative liability	13
Total short-term liabilities at fair value	$ 13

FAIR VALUE MEASUREMENTS (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Ending Balance	$ 13
Derivative [Member]
Beginning Balance	0	$ (5)
Inception of derivative liability	5
Change in fair value during the year	7	5
Ending Balance	$ 12	$ 0

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			1 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Aug. 03, 2024	Jul. 04, 2023	Jul. 31, 2024	Jul. 23, 2024	Jul. 22, 2024	Jun. 28, 2024	Apr. 15, 2024	Aug. 13, 2024	Jun. 30, 2024	Dec. 31, 2023	Dec. 17, 2019
Convertible promissory note											$ 2,400,000
Monthly Installments		$ 12,041				$ 20,000	$ 2,000
Common Stock, Issued									56,267,000	54,105,000
Interest payment									$ 143,000	$ 188,000
Subsequent Event [Member]
Warrants strike price			$ 0.25
Description of issuance of common stock			we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense
Common Stock, Issued			75,000
Subsequent Event [Member] \| Finder's Fee Agreement [Member]
Annual interest rate	9.00%
Common stock, warrants issued	400,000
Subsequent Event [Member] \| Unaffiliated Third Party [Member]
Convertible promissory note				$ 50,000				$ 25,000
Monthly Installments				$ 10,000
Warrants strike price				$ 0.25
Warrants expire date				Jul. 31, 2028
Common Stock, Issued				60,000
Accrued interest				$ 5,000
Interest payment				$ 5,000
Debt maturity date				Feb. 01, 2025
Subsequent Event [Member] \| Diagonal Lending [Member]
Convertible promissory note					$ 62,100
Monthly Installments					8,849
Discount on convertible note					8,100
Accrued interest					8,694
Due to convertible notes					$ 35,397
Debt maturity date					May 30, 2025

Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Guided Therapeutics (QB) Charts.

Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GTHP Guided Therapeutics Inc (QB)

News Guided Therapeutics Inc (QB)

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GTHP Guided Therapeutics Inc (QB)

News Guided Therapeutics Inc (QB)

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen